***Manuscript Category*:** Original Article

Comparative efficacy of different eating patterns in the management of type 2 diabetes and prediabetes: An arm-based Bayesian network meta-analysis

***Authors*:** Ben-tuo Zeng[1], Hui-qing Pan[2], Feng-dan Li[3], Zhen-yu Ye[1], Yang Liu[1†] and Ji-wei Du[4†]

Affiliations:

[1] School of Medicine, Xiamen University, Xiamen 361102, China

[2] School of Medicine, Tongji University, Shanghai 200331, China

[3] Nursing Department, Xiang'an Hospital of Xiamen University, Xiamen 361102, China

[4] Nursing Department, The University of Hong Kong–Shenzhen Hospital, Shenzhen 518040, China

Correspondence:

Ji-wei Du, 1 Haiyuan 1st Road, Futian, Shenzhen 518040, China. E-mail: dujw@hku-szh.org; Tel.: +86-15359350116

Yang Liu, 4221 Xiang'an Road (South), Xiang'an, Xiamen 361102, China. E-mail: liuyang123@xmu.edu.cn; Tel.: +86-18150115008

***Short Title**:* Diet Network Meta-analysis for Diabetes

Word Count: 3,808

† Corresponding authors.

Abstract:

***Aims/Introduction*:** Diet therapy is a vital approach to manage type 2 diabetes and prediabetes. However, the comparative efficacy of different eating patterns is not clear enough. We aimed to compare the efficacy of various eating patterns for glycemic control, anthropometrics, and serum lipid profiles in the management of type 2 diabetes and prediabetes.

***Materials and Methods*:** We conducted a network meta-analysis using arm-based Bayesian methods and random effect models, and drew the conclusions using the partially contextualized framework. We searched twelve databases and yielded 9,534 related references, where 107 studies were eligible, comprising 8,909 participants.

***Results*:** Eleven diets were evaluated for fourteen outcomes. Caloric restriction was ranked as the best pattern for weight loss (SUCRA 86.8%) and waist circumference (82.2%), low-carbohydrate diets for body mass index (81.6%) and high-density lipoprotein (84.0%), and low-glycemic-index diets for total cholesterol (87.5%) and low-density lipoprotein (86.6%). Other interventions showed some superiorities, but were of imprecision due to insufficient participants and needed further investigation. The attrition rates of interventions were similar. Meta-regression suggested that macronutrients, energy intake, and weight may modify outcomes differently. The evidence was of moderate-to-low quality, and 38.2% of the evidence items met the minimal clinically important differences.

***Conclusions*:** The selection and development of dietary strategies for diabetic/prediabetic patients should depend on their holistic conditions, i.e., serum lipids profiles, glucometabolic patterns, weight and blood pressures. It is recommended to identify the most critical and urgent metabolic indicator to control for one specific patient, and then choose the most appropriate eating pattern accordingly.

***Keywords*:** diabetes mellitus, type 2; medical nutrition therapy; prediabetic state

1. Introduction

It was estimated that 10.5% of people aged 20-75 suffered from diabetes mellitus globally, where over 90% were type 2 diabetes (T2DM) [1]. They spend about 966 billion US dollars of health expenditures per year[1]. Since T2DM has proven to be preventable and controllable[2], the remission of a

prediabetic state (PreD), or impaired glucose tolerance (IGT), was also concerned and included in the comprehensive prevention of T2DM incidence.

Beyond medications, lifestyle management is more cost-effective for T2DM/PreD patients with strong clinical evidence[3-5], where eating patterns play the leading role. Various patterns of different nutrients and food groups have been investigated and applied to T2DM/PreD treatment and management, from the very high-fat diet in the 18th century[6] to the pattern recommended by American Diabetes Association (ADA) in 2003[7]. From an evidence-based perspective, hundreds of random controlled trials (RCT), cohorts, and related systematic reviews have quantified the efficacy of popular and widely-used eating patterns[8-13].

However, there are variances in the effectiveness of the diets across different outcomes, e.g., blood glucose, weight, and cardiovascular risk factors. Diabetes Canada guidelines[4] summarized the properties of dietary interventions, pointing out the differences among diets. Consequently, current guidelines strongly recommend an individualized medical nutrition therapy under the supervision of dietitians and multidisciplinary professionals[3-5]. However, how to choose and apply appropriate dietary patterns for professionals remains to be a question, due to the lack of direct evidence comparing relative efficacy of the interventions. Whether a specific diet is proper for an individual with specific laboratory profiles and situations is not clear enough, though high-quality evidence of several patterns has been drawn.

It is not cost-effective to carry out multi-arm trials directly comparing several diets. Thus, it is crucial to conduct a network meta-analysis to synthesize current evidence. Previous network meta-analyses[14, 15] have assessed a number of patterns, but the authors only included a limited number of studies and outcomes. Furthermore, short-term trials were not considered in the analyses, but a short-term effect may be more common for some patterns[16]. Therefore, this study aimed to evaluate the relative efficacy of different eating patterns on glycemic control, anthropometrics and serum lipid profiles in the management of T2DM/PreD patients, and conclude evidence to promote clinical decision-making.

2. Materials & Methods

2.1. Study Design

We conducted an arm-based Bayesian network meta-analysis of randomized controlled trials, following the Cochrane Handbook[17]. We reported results according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses Incorporating Network Meta-analysis (PRISMA-NMA)[18]. A protocol was prepared and registered a priori in PROSPERO (CRD42021278268).

2.2. Eligibility Criteria

We selected peer-reviewed articles and thesis according to the PICOS principle. Eligibility criteria are displayed in Table 1.

2.3. Search Strategy

We conducted searches of databases and trial registers, including PubMed, Web of Science, Embase, CINAHL and Open Dissertation, ProQuest, Scopus, Global Index Medicus, Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, SinoMed, WanFang Med, and CNKI. All publications from the inception to 13 October 2021 were initially retrieved. An updated search was conducted on March 17, 2022 using Scopus and Google Scholar to identify the latest relevant articles. Full search strategy can be found in File S1.

2.4. Data Selection and Extraction

All references identified from the search were imported into EndNote 20 (Clarivate, PA, USA) to move duplicates. After automatic exclusion by filtering title using excluding terms, reviewers (B.-T.Z., H.-Q.P., and F.-D.L.) assessed the eligibility in the order of title, abstract and full text. Each reference was decided independently by at least two reviewers, and arisen discrepancies were discussed and decided by the authors together.

We used MySQL 8.0 (Oracle Corporation, TX, USA) for data extraction and management, and critical information was extracted (see File S2 for fields in MySQL tables). Two authors (B.-T.Z. and Z.-Y.Y.) independently extracted the data and checked the consistency.

R 4.1.3 (R Foundation, Vienna, Austria) and Microsoft Excel 2019 (Microsoft Corporation, WA, USA) were used for data conversion and imputation. For continuous outcomes, we calculated the change from baseline and its standard deviation (SD) if not reported by the article. Correlation

coefficients for changes from baseline and for crossover RCTs were estimated using reported SDs from included studies (File S3). Median and interquartile range was converted into mean and SD using methods from Luo[19] and Wan[20] after testing for skewness using methods from Shi et al.[21]. WebPlot Digitizer[22] was applied for extracting data from figures. Ultimately, R package "mice"[23] was used for the imputation of missing values of covariates for meta-regression.

2.5. Risk of Bias Assessment

The Risk of Bias 2 tool[24] and Risk of Bias 2 for crossover trials[25] were employed to assess the risk of bias (RoB) of parallel and crossover RCTs, respectively. Two reviewers (B.-T.Z. and H.-Q.P.) assessed the RoBs independently, with all arisen divergences discussed and reached consensuses.

2.6. Data Synthesis

Our study synthesized evidence through an arm-based Bayesian network meta-analysis in a random effect model. We use R package "gemtc" 1.0-1 for meta-analysis, inconsistency test, heterogeneity test, meta-regression, and sensitivity analysis[26, 27]. Markov chain Monte Carlo sampling was performed using JAGS 4.3.0 via R package "rjags" 4.12[28, 29]. Comparison-adjusted funnel plots, Egger's test, and Begg's test were performed to detect publication bias under a frequentist framework and random effect model using R package "netmeta" 2.1-0 and "metafor" 3.4-0[30, 31].

Continuous outcomes were presented as mean difference (MD) or difference in percentage change from baseline (Percentage MD, PMD, for fasting insulin and insulin resistance) and 95% credible intervals (95% CrI), while relative risk (RR) and 95% CrI were for dichotomous variables.

2.7. Quality of the Evidence

We rated the quality of evidence of comparisons of experimental diets and control diets based on the GRADE Working Group's network meta-analysis evidence rating strategies[32] and the GRADE handbook[33]. Conclusions were drawn according to the partially contextualized framework by the GRADE workgroup[34], where minimal clinically important differences (MCID) and thresholds

for moderate and large beneficial/harm effects were identified based on previous studies[13, 35-37] and consensuses among reviewers.

3. Results

We identified 9,358 publications and registrations from the initial search, and 176 from the updated search. 111 publications[38-148] were eligible, where 107 independent studies were identified (Figure 1). All items excluded via full-text screening and their reason for exclusion were listed in File S4.

Among our prescribed outcomes, data of FPG, HbA_{1c}, FIns, IR, weight, BMI, WC, SBP, DBP, TG, TC, HDL, LDL, and attrition rate were sufficient to form networks and perform a meta-analysis. However, other outcomes were not analyzed due to scarce data.

3.1. Study characteristics

The 107 included studies contained 8,909 participants for data analysis and 8,583 completers. A total of ten experimental diets and 223 arms was reported. The studies reported efficacy of CR, DASH, fiber, HFD, HPD, LCD, LGID, Med, Paleo, and VD, but ND and PfD were not included.

Characteristics of the studies are displayed in Table 2. We included 16 crossover and 91 parallel RCTs. Among them, seven were multi-arm, and six were multicenter. Four studies reported their outcomes in two or more publications. Only five studies focused on PreD population; considering that there was not significant difference among PreD and T2DM RCTs, we did not distinguish them in the meta-analysis. Fundings and conflicts of interest of the studies are listed in File S5.

3.2. Risk of Bias Assessment

The overall risk of bias of eligible studies was acceptable, but trials of some patterns (fiber and DASH) had a relatively high risk of bias (Table 2). 15.9% of studies were at high risk of bias (Figure 2). Notably, the risk of bias of crossover RCTs was significantly higher than the parallel ($P_{0.05/2}$=0.006, Mann-Whitney test), due to the period and carryover effects. Detailed risk of bias ratings of each domain are displayed in File S6.

3.3. Main Outcomes

The number of nodes and comparisons varied among outcomes (Figure 3 and File S7). File S8 presented all league tables and cumulative ranking curves; File S9 showed forest plots with heterogeneity and inconsistency tests of all outcomes.

3.3.1 Glycemic Control

For glycemic control, high-fiber diet (fiber) was ranked as the best pattern for reducing FPG (MD -1.3 mmol/L, 95% CrI -2.3 to -0.22, SUCRA 82.7%) (Figure 3A). DASH (-1.2%, -2.2 to -0.23, SUCRA 90.5%) and LGID (-0.71%, -0.93 to -0.49, SUCRA 76.2%) had the highest probability of improving HbA_{1c} compared with control groups (Figure 3B). The effects on reducing FPG and HbA_{1c} were comparable.

FIns and IR were presented as PMD due to the various units reported by studies. Effects on improving insulin-related conditions were not stable and significant because of the limited sample size. High-fiber diets achieved a mean of 21% Fins reduction (95% CrI 5.2% to 46%) with a probability of 79.4% to be the best pattern (Figure 3C). IR was reported as homeostatic model assessment (HOMA)1-IR and HOMA2-IR, among which HPD showed the best beneficial effects on improving IR (-22%, -37% to -7.0%, SUCRA 86.3%) (Figure 3D).

3.3.2 Anthropometrics

CR was still one of the most effective diet patterns for weight loss (-4.1 kg, -6.1 to -2.0, SUCRA 86.8%) and WC (-4.5 cm, -7.4 to -1.8, SUCRA 82.2%), and LCD was ranked as the second (-3.0 kg, -4.3 to -1.8, SUCRA 74.3%) for weight loss and the best (-1.2 kg/m^2, -1.7 to -0.74, SUCRA 81.6%) for BMI reduction (Figure 3E-G).

As for blood pressure, DASH was found to be the best pattern for lowering SBP (-7.6 mmHg, -15 to -0.29, SUCRA 87.9%) and the second for DBP (-3.7 mmHg, -10 to 2.8, SUCRA 73.7%), while HPD was the most effective for DBP (-3.0 mmHg, -5.9 to -0.068, SUCRA 74.6%) with slight superiority to DASH (Figure 3I-J).

3.3.3 Lipid Profiles

Figure 3K-N illustrated different interventions' effects on lipid profiles comparing with control groups. LGID showed the most remarkable efficacy for lowering TC (-0.46 mmol/L, -0.62 to -0.30,

SUCRA 87.5%) and LDL (-0.35 mmol/L, -0.47 to -0.24, SUCRA 86.6%), but were not of beneficial effects on HDL. Paleo was ranked as the best pattern for improving TG (-0.50 mmol/L, -1.1 to 0.13, SUCRA 83.4%), though the outcome was not statistically significant. LCD led to an average increase of 0.12 mmol/L (95% CrI 0.073 to 0.17, SUCRA 84.0%) for HDL compared to control, thus being the best intervention with a small effect size.

3.3.4 Attrition

Since a considerable number of studies did not report standardized flowcharts of follow-up, we only included trials that reported a loss in at least one arm into synthesis. An attrition rate was calculated as: the attrition number divided by the product of participant number when allocation and the duration of intervention. The meta-analysis did not find significant difference among all patterns (Figure 3H; File S8), suggesting that participants' tolerance for each diet be similar.

3.4. Heterogeneity and Inconsistency Test

Generally, the included interventions were of moderate to high heterogeneity (Figure 3, File S9, and File S10), making the results less confident. LCD-control, CR-control, LGID-control, LCD-CR, and LGID-LCD pairs were of high heterogeneity in either direct or network comparison, while Med-control and HPD-control were with mild heterogeneity in lipid profiles. Significant inconsistency was observed in LCD-CR for FPG, and CR-LCD-control loop for weight and LDL using node-splitting methods. The evidence of CR, LCD and LGID showed severe incoherence and inconsistency and should be interpreted prudently.

3.5. Meta-regression

A random effect meta-regression model with one covariate and exchangeable coefficients was fitted for continuous outcomes. The significance of coefficients was summarized in File S11. Universally, the meta-regression denoted that weight, BMI, and macronutrient intake significantly modified the efficacy of interventions of most outcomes. On the contrary, coefficients of length, study design, medication or insulin treatment, duration of disease, and sex ratio were not significant, implying that these factors may not contribute to the effectiveness. Another notable finding that

coefficients of sample size and origin (from China or not) showed significance in FPG, weight, and lipid profiles indicated potential publication or selection biases.

3.6. Sensitivity Analysis

Effect of Weight, BMI, and TC showed robustness, but other outcomes were not robust enough (File S12). The exclusion of several articles[51, 61, 67, 97, 98, 101, 126, 134, 135, 140, 145] significantly changed the SUCRA and the 95% CrI of effect size, mainly in comparisons of CR, LCD, and Med vs. control, contributing to the severe heterogeneity. When testing for different models, i.e., fixed effect or unrelated study effect models, Med, HPD, and VD showed narrower 95% CrIs and became statistically significant for more outcome variables (see File S12). The analysis did not observe the sensitivity of relative effect and between-study heterogeneity priors, and correlation coefficients.

3.7. Publication Bias

Potential publication bias of HbA_{1c}, weight and BMI existed (Egger's test $P = 0.002$; < 0.001; and < 0.001, respectively). P values for all outcomes and comparison-adjusted funnel plots were listed in File S13.

3.8. Quality of Evidence

All MCIDs and thresholds were identified (see File S14, Figure 3, and Table 3). Of all 123 pieces of evidence comparing interventions and control groups, 49 were of moderate quality, and there was no high-quality evidence (Table 3). At the clinical level, all patterns were not significantly worse than control diets for each outcome, but most did not show moderate to large beneficial effects. All the quality of evidence should be downgraded when applying to PreD due to the indirectness, because PreD-related trials were limited.

4. Discussion

This review evaluated the comparative efficacy of ten experimental diets, and the results can provide guidance for diet selection of one specific patients. To manage patients with comorbidities and different levels of glycemic control, we concluded a dietary suggestion table derived from the

evidence from the meta-analysis (Table 4). However, this table should be applied prudently because the evidence was not solid enough.

4.1. Quantity of Macronutrients

A previous evidence basis has corroborated the efficacy of CR in weight loss, BMI and WC in patients with metabolic diseases or healthy individuals[149, 150]. However, CR did not lead to greater improvement of glycemic control, blood pressure, TG, and TC compared to standard diets. Trivial effects on these outcomes may result from weight loss but not the caloric restriction[151, 152]. The median TEI of the included CR arms was 1594 kcal/d, with a 150-to-400-kcal negative difference compared to standard diets, significantly slighter than the prescribed (-500 kcal/d). However, the deviance did not lead to the failure of trials. The phenomena were also observed in LCD and LGID.

Carbohydrate restriction acted well in weight, HbA_{1c}, TG, and HDL, where improving HDL was the unique advantage of LCD. Nevertheless, other types of serum lipids, i.e., TC and LDL were not improved. The 75th percentile of carbohydrate intake of the included LCD arms was 40%, indicating that nearly a quarter of included trials did not meet the low-carbohydrate criteria as prescribed. Nevertheless, the effect size was similar to previous systematic reviews[13], and the strict following of the instruction as well as a more intensive intervention did not enhance the effects but may even lead to a decrease (File S11).

Increased protein intake without carbohydrate restriction (HPD) effectively improved IR, blood pressure and TG. Compared to other review[153], the effectiveness of HPD on FPG, HbA_{1c} and other lipids was not observed, mainly due to the different inclusion criteria: only HPD with protein intake of more than 30% TEI and without carbohydrate restriction was included. This implied the different efficacy of protein and carbohydrate.

As for HFD, no beneficial effect was detected, and fat intake negatively modified the lipid improvement. Despite the numerical impact on specific lipids, it remained to be evaluated whether specific types of fat improved or negatively affected the overall lipoprotein profile[154]. Unfortunately, the included trials did not provide sufficient data to draw a thorough interpretation.

4.2. Quality of Carbohydrates

LGID and high-fiber diets emphasized more on the quality of carbohydrates. Effects of LGID and high-fiber diets were similar: both showed more excellent effects on FPG, HbA_{1c}, FIns, TC, and LDL than other patterns, but did not significantly improve weight-related outcomes, consistent with other studies[155, 156]. Dietary GI and fiber of specific single food were not well-associated[157]. However, the emphasis on lowering GI may encourage participants to increase fiber intake, because the usually recommended food groups can be both low in GI and high in fiber, e.g., whole grains and nuts.

A recent high-quality meta-analysis has also denoted that dietary fiber and low-GI food were associated with a lower risk of T2DM incidence, where fiber may be a stronger protector[158]. Rather than a severe long-term restriction of carbohydrate intake which leads to higher all-cause mortality[159], LGID and increased fiber intake can be better and sustainable approaches for T2DM patients without obesity/overweight, especially with the circumstance that most people lacked fiber intake[160].

4.3. Mediterranean Diets

Even if previous cohort studies and RCTs have demonstrated the efficacy of Med in T2DM management[161], our study failed to detect a significant improvement driven by Med. Except for HbA_{1c}, IR and TG, all other outcomes were of great imprecision and trivial effects. The effect size was also more trivial than other meta-analyses[14, 162]. Small sample size compared to other interventions could be the reason when using random effects models; different calculation of effect size, i.e., MD of change from baseline or of endpoint may explain the numerical differences.

Moreover, heterogeneity was detected for almost all outcomes of Med-control comparisons, where the variance and bias of the definition of Med in different trials[163] can be a significant reason. Though several scales have been developed to measure the adherence to Med (e.g., MedDiet Score)[164], few trials employed it, making this problem difficult to address.

4.4. Vegan, Vegetarian, or Plant-based Diets

VD did not show any significant beneficial effects in our study. The mean differences of VD were similar to the previous studies[36], thus not affecting the conclusion but lowering the quality of

evidence. While using fixed effect models, the effectiveness of VD on BMI, WC, and HbA_{1c} was detected, but moderate heterogeneity made it unreasonable to employ fixed effect models.

Notably, the carbohydrate intake in VD trials was relatively high (mean 65.8%TEI). The sensitivity analysis also showed a slight improvement of SUCRA in TG after omitting Lee 2016[91], which contained about 72%TEI of carbohydrate in VD arms. Researchers should consider a lower carbohydrate intake when conducting VD, and the effects would promise to be more significant.

4.5. Newly-developed diets

Evidence of the efficacy of DASH and Paleo was limited and of low quality due to the sample size, and further investigation is needed. As one of the recommended healthy patterns by Dietary Guidelines for Americans (DGA 2020-2025)[165], many studies have addressed DASH's benefit in blood pressure and glycemic control[166, 167]. However, related RCTs specially for T2DM/PreD patients were rare. Included studies also outlined the beneficial effects of DASH on blood pressure, TC, LDL, and HbA_{1c}, and DASH was the most effective intervention for HbA_{1c} with a high probability (90.5%). As for Paleolithic diets, Tommy Jönsson and his colleagues quantified the improvement of leptin and introduced a scale (Paleolithic Diet Fraction) to measure the compliance, based on their trial[87, 168], providing a basis for further studying.

4.6. Limitations

This study had several limitations. First, the heterogeneity and sensitivity lowered the quality of evidence. Second, the sample size of VD, DASH, and Paleo was limited, leading to the imprecision. Third, only five PreD trials were included, raising the indirectness of the evidence for PreD population. Moreover, there was not an adequate method to compare the longitudinal dataset of different patterns, though the data of different timepoints have been extracted.

In conclusion, Energy, carbohydrate, and dietary glycemic index (GI) restriction, as well as dietary fiber intake, were the most effective approaches with solid and abundant evidence bases. Simultaneously, DASH, Paleolithic diets, and HPD were of satisfactory efficacy in limited outcomes

and worth investigation. Mediterranean diets, VD and HFD did not act well in most outcomes, mainly due to the imprecision. Heterogeneity and sensitivity should be concerned when interpreting results.

This work may eliminate some barriers on how to choose the best diet on an individualized basis. Clinicians and dietitians can choose the most important outcome that in an urgent need to control for a patient to match the most appropriate dietary pattern, according to the summary of finding table and the dietary suggestion table of this review.

Acknowledgments: We acknowledge Professor Lawrence J. Cheskin from George Mason University for his kindly replying our email about the data availability of his registered trial. This research did not receive any funding.

Disclosure of Ethical Statements:

Approval of the research protocol: N/A.

Informed consent: N/A.

Registry and the registration no. of the study/trial: This network meta-analysis was registered at https://www.crd.york.ac.uk/PROSPERO as CRD42021278268.

Animal studies: N/A.

Disclosure Statement: The authors declare no conflict of interest.

References

1. International Diabetes Federation. IDF Diabetes Atlas. 10 edn. Brussels: International Diabetes Federation; 2021.

2. Gong Q, Zhang P, Wang J, *et al.* Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. *Lancet Diabetes Endocrinol* 2019;7(6):452-61.

3. American Diabetes Association Professional Practice Committee. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes—2022. *Diabetes Care* 2021;45(Supplement_1):S60-S82.

4. Sievenpiper JL, Chan CB, Dworatzek PD, *et al.* Nutrition Therapy. *Can J Diabetes* 2018;42:S64-S79.

5. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management 2015 [updated 31 Mar 2022; cited 3 May 2022]. Available from: www.nice.org.uk/guidance/ng28.

6. White P. Diabetes in Childhood and Adolescence. Philadelphia: Lea & Febiger; 1932.

7. American Diabetes Association. Standards of Medical Care for Patients With Diabetes Mellitus. *Diabetes Care* 2003;26(suppl_1):s33-s50.

8. Lean MEJ, Leslie WS, Barnes AC, *et al.* Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol* 2019;7(5):344-55.

9. Martínez-González MÁ, Corella D, Salas-Salvadó J, *et al.* Cohort Profile: Design and methods of the PREDIMED study. *Int J Epidemiol* 2010;41(2):377-85.

10. Mitrou PN, Kipnis V, Thiébaut ACM, *et al.* Mediterranean Dietary Pattern and Prediction of All-Cause Mortality in a US Population: Results From the NIH-AARP Diet and Health Study. *Arch Intern Med* 2007;167(22):2461-8.

11. Riboli E, Hunt KJ, Slimani N, *et al.* European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* 2002;5(6b):1113-24.

12. Stevens J, Ahn K, Juhaeri, *et al.* Dietary Fiber Intake and Glycemic Index and Incidence of Diabetes in African-American and White Adults: The ARIC Study. *Diabetes Care* 2002;25(10):1715-21.

13. Goldenberg JZ, Day A, Brinkworth GD, *et al.* Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. *BMJ* 2021;372:m4743.

14. Schwingshackl L, Chaimani A, Hoffmann G, *et al.* A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. *Eur J Epidemiol* 2018;33(2):157-70.

15. Pan B, Wu Y, Yang Q, *et al.* The impact of major dietary patterns on glycemic control, cardiovascular risk factors, and weight loss in patients with type 2 diabetes: A network meta-analysis. *J Evid Based Med* 2019;12(1):29-39.

16. McArdle PD, Greenfield SM, Rilstone SK, *et al.* Carbohydrate restriction for glycaemic control in Type 2 diabetes: a systematic review and meta-analysis. *Diabet Med* 2019;36(3):335-48.

17. Higgins J, Thomas J, Chandler J, *et al.* Cochrane Handbook for Systematic Reviews of Interventions version 6.2: Cochrane; 2021 [updated Feb 2021; cited 17 Feb 2022]. Available from: www.training.cochrane.org/handbook.

18. Hutton B, Salanti G, Caldwell DM, *et al.* The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162(11):777-84.

19. Luo D, Wan X, Liu J, *et al.* Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res* 2018;27(6):1785-805.

20. Wan X, Wang W, Liu J, *et al.* Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;14(1):1-13.

21. Shi J, Luo D, Wan X, *et al.* Detecting the skewness of data from the sample size and the five-number summary. *arXiv preprint arXiv:201005749* 2020.

22. Rohatgi A. WebPlotDigitizer 4.5 [updated Aug 2021; cited 28 Jan 2022]. Available from: https://automeris.io/WebPlotDigitizer.

23. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *J Stat Softw* 2011;45(3):1 - 67.

24. Sterne JA, Savović J, Page MJ, *et al.* RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366.

25. Higgins J, Tianjing L, Jonathan S. Revised Cochrane risk of bias tool for randomized trials (RoB 2) Additional considerations for crossover trials 2021. Available from: https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/rob-2-for-crossover-trials?authuser=0.

26. van Valkenhoef G, Dias S, Ades AE, *et al.* Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. *Res Synth Methods* 2016;7(1):80-93.

27. van Valkenhoef G, Lu G, de Brock B, *et al.* Automating network meta - analysis. *Res Synth Methods* 2012;3(4):285-99.

28. Lunn D, Spiegelhalter D, Thomas A, *et al.* The BUGS project: Evolution, critique and future directions. *Stat Med* 2009;28(25):3049-67.

29. Plummer M, Best N, Cowles K, *et al.* CODA: convergence diagnosis and output analysis for MCMC. *R News* 2006;6(1):7-11.

30. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. *Res Synth Methods* 2012;3(2):161-76.

31. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Softw* 2010;36(3):1 - 48.

32. Puhan MA, Schünemann HJ, Murad MH, *et al.* A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014;349:g5630.

33. GRADE Working Group. GRADE Handbook 2013 [updated September 2013; cited 10 Apr 2022]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html.

34. Brignardello-Petersen R, Izcovich A, Rochwerg B, *et al.* GRADE approach to drawing conclusions from a network meta-analysis using a partially contextualised framework. *BMJ* 2020;371:m3907.

35. Ramachandran A, Riddle MC, Kabali C, *et al.* Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. *Diabetes Care* 2012;35(4):749-53.

36. Viguiliouk E, Kendall CWC, Kahleová H, *et al.* Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes: A systematic review and meta-analysis of randomized controlled trials. *Clin Nutr* 2019;38(3):1133-45.

37. Johnston BC, Kanters S, Bandayrel K, *et al.* Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults: A Meta-analysis. *JAMA* 2014;312(9):923-33.

38. Al-Jazzaf B. Dietary approaches for the reduction of cardiovascular disease risk in type 2 diabetes mellitus and obesity [Ph.D.]. Ann Arbor: University of Surrey (United Kingdom); 2007.

39. Azadbakht L, Fard NR, Karimi M, *et al.* Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. *Diabetes Care* 2011;34(1):55-7.

40. Bahado-Singh PS, Riley CK, Wheatley AO, *et al.* High fiber Caribbean diets with low-intermediate GI improve glycemic control, cardiovascular and inflammatory indicators in overweight persons with type 2 diabetes: A randomized control study. *Current Research in Nutrition and Food Science* 2015;3(1):36-45.

41. Barnard ND, Cohen J, Jenkins DJ, *et al.* A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial. *Am J Clin Nutr* 2009;89(5):1588s-96s.

42. Barnard ND, Cohen J, Jenkins DJA, *et al.* A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. *Diabetes Care* 2006;29(8):1777-83.

43. Brand JC, Colagiuri S, Crossman S, *et al.* Low-Glycemic Index Foods Improve Long-Term Glycemic Control in NIDDM. *Diabetes Care* 1991;14(2):95-101.

44. Brehm BJ, Lattin BL, Summer SS, *et al.* One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. *Diabetes Care* 2009;32(2):215-20.

45. Breukelman GJ, Basson AK, Djarova TG, *et al.* Concurrent low-carbohydrate, high-fat diet with/without physical activity does not improve glycaemic control in type 2 diabetics. *South Afr J Clin Nutr* 2021;34(1):18-21.

46. Breukelman GJ, Basson AK, Djarova TG, *et al.* Combination Low Carbohydrate, High Fat Diet and Physical Activity Intervention on Lipoprotein-Lipids in Type 2 Diabetics. *Asian J Sports Med* 2019;10(4):1-7.

47. Brinkworth GD, Noakes M, Parker B, *et al.* Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: one-year follow-up of a randomised trial. *Diabetologia* 2004;47(10):1677-86.

48. Brunerova L, Smejkalova V, Potockova J, *et al.* A comparison of the influence of a high-fat diet enriched in monounsaturated fatty acids and conventional diet on weight loss and metabolic parameters in obese non-diabetic and Type 2 diabetic patients. *Diabet Med* 2007;24(5):533-40.

49. Cao A-H, Sun L-Z, Cui J-W, *et al.* Effects of a low-carbohydrate diet and a low-fat diet on weight and glycemic control in type 2 diabetes mellitus. *Chin Gen Pract* 2011;14(1):52-3;6. (Chinese).

50. Ceriello A, Esposito K, Sala LL, *et al.* The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: A preliminary report. *Cardiovasc Diabetol* 2014;13(1).

51. Chandalia M, Garg A, Lutjohann D, *et al.* Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. *N Engl J Med* 2000;342(19):1392-8.

52. Chen CY, Huang WS, Chen HC, *et al.* Effect of a 90 g/day low-carbohydrate diet on glycaemic control, small, dense low-density lipoprotein and carotid intima-media thickness in type 2 diabetic patients: An 18-month randomised controlled trial. *PLoS One* 2020;15(10):e0240158.

53. Chen X, Su H, Kunii D, *et al.* The Effects of Mobile-App-Based Low-Carbohydrate Dietary Guidance on Postprandial Hyperglycemia in Adults with Prediabetes. *Diabetes Ther* 2020;11(10):2341-55.

54. Choi KM, Han KA, Ahn HJ, *et al.* The effects of caloric restriction on fetuin-A and cardiovascular risk factors in rats and humans: a randomized controlled trial. *Clin Endocrinol (Oxf)* 2013;79(3):356-63.

55. Coppell KJ, Kataoka M, Williams SM, *et al.* Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment - Lifestyle over and above drugs in diabetes (LOADD) study: Randomised controlled trial. *BMJ (Online)* 2010;341(7766):237.

56. Coulston AM, Hollenbeck CB, Swislocki ALM, *et al.* Persistence of hypertriglyceridemic effect of low-fat high-carbohydrate diets in NIDDM patients. *Diabetes Care* 1989;12(2):94-101.

57. Daly ME, Paisey R, Paisey R, *et al.* Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes--a randomized controlled trial. *Diabet Med* 2006;23(1):15-20.

58. Davis NJ, Tomuta N, Schechter C, *et al.* Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. *Diabetes Care* 2009;32(7):1147-52.

59. Ding H, Shao J, Zhe W, *et al.* The Application of Low Glycemic Index Diet in Nutrition Intervention to Uygur Patients with Diabetes. *Chin J Prev Control Chronic Dis* 2010;18(2):123-4;8. (Chinese).

60. Ding H, Shao J, Zhe W, *et al.* Application of low glycemic index diet in diabetes of Uygur and its effect on biochemical indicators. *Acta Nutr Sin* 2010;32(5):460-2. (Chinese).

61. Durrer C, McKelvey S, Singer J, *et al.* A randomized controlled trial of pharmacist-led therapeutic carbohydrate and energy restriction in type 2 diabetes. *Nat Commun* 2021;12(1):5367.

62. Elhayany A, Lustman A, Abel R, *et al.* A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. *Diabetes Obes Metab* 2010;12(3):204-9.

63. Esposito K, Maiorino MI, Ciotola M, *et al.* Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. *Ann Intern Med* 2009;151(5):306-14.

64. Fabricatore AN, Wadden TA, Ebbeling CB, *et al.* Targeting dietary fat or glycemic load in the treatment of obesity and type 2 diabetes: a randomized controlled trial. *Diabetes Res Clin Pract* 2011;92(1):37-45.

65. Fan C, Chen L, Wang H. Practice of employing a low glycemic index dietary regimen in dietary guidance for elderly diabetic patient. *J Nurs Sci* 2013;28(7):77-9. (Chinese).

66. Fan L, Duan A, Xue Z, *et al.* Effect of low glycemic index diet in the clinical treatment of diabetes mellitus. *Chin Gen Nurs* 2010;8(19):1711-2. (Chinese).

67. Fang F. Analysis of the Effects of Low-medium Caloric Diet on Overweight or Obese Patients with Type 2 Diabetes Mellitus. *Diabetes New World* 2019;22(13):49-51. (Chinese).

68. Fang R. Effect of low glycemic index diet on glucose and lipid metabolism in elderly patients with type 2 diabetes mellitus in the community. *Chin J Health Care Med* 2016;18(3):243-4. (Chinese).

69. Gannon MC, Nuttall FQ. Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. *Diabetes* 2004;53(9):2375-82.

70. Gannon MC, Nuttall FQ, Saeed A, *et al.* An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. *Am J Clin Nutr* 2003;78(4):734-41.

71. Goldstein T, Kark JD, Berry EM, *et al.* The effect of a low carbohydrate energy-unrestricted diet on weight loss in obese type 2 diabetes patients - A randomized controlled trial. *e-SPEN* 2011;6(4):e178-e86.

72. Gram-Kampmann EM, Hansen CD, Hugger MB, *et al.* Effects of a six-month low-carbohydrate diet on glycemic control, body composition and cardiovascular risk factors in patients with type 2 diabetes: an open-label RCT. *Diabetes Obes Metab* 2022;24(4):693-703.

73. Guldbrand H, Dizdar B, Bunjaku B, *et al.* In type 2 diabetes, randomisation to advice to follow a low-carbohydrate diet transiently improves glycaemic control compared with advice to follow a low-fat diet producing a similar weight loss. *Diabetologia* 2012;55(8):2118-27.

74. Guo L, Du N, Zhu J, *et al.* Effect of low glycemic index diet on the metabolism of 243 patients with type 2 diabetes mellitus. *China Health Care Nutr* 2014;7:4260. (Chinese).

75. Han Y, Cheng B, Guo Y, *et al.* A Low-Carbohydrate Diet Realizes Medication Withdrawal: A Possible Opportunity for Effective Glycemic Control. *Front Endocrinol (Lausanne)* 2021;12.

76. Hashemi R, Rahimlou M, Baghdadian S, *et al.* Investigating the effect of DASH diet on blood pressure of patients with type 2 diabetes and prehypertension: Randomized clinical trial. *Diabetes Metab Syndr* 2019;13(1):1-4.

77. He L, Meng G, Chen W, *et al.* Effects of hypoglycemia index and hypoglycemia loaded diet on oxidative stress and anthropometric parameters in patients with type 2 diabetes mellitus. *Chin J Pract Nurs* 2017;33(5):347-51. (Chinese).

78. Heilbronn LK, Noakes M, Clifton PM. The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. *J Am Coll Nutr* 2002;21(2):120-7.

79. Hockaday TDR, Hockaday JM, Mann JI, *et al.* Prospective comparison of modified-fat–high-carbohydrate with standard low-carbohydrate dietary advice in the treatment of diabetes: one year follow-up study. *Br J Nutr* 1978;39(2):357-62.

80. Hu X, Gu Q, Lu D, *et al.* Effect of diets with different carbohydrate contents and exercise on cardiovascular risk factors in people with prediabetes. *Pract Clin Med (Jiangxi)* 2018;19(5):1-5. (Chinese).

81. Huang J, Shen H, Li M. Application of low glycemic index dietary regimen in dietary education for elderly type 2 diabetic patients. *Nurs Integr Tradit Chin West Med* 2016;2(4):86-8. (Chinese).

82. Ikem RT, Kolawole BA, Ojofeitimi EO, *et al.* A controlled comparison of the effect of a high fiber diet on the glycaemic and lipid profile of Nigerian clinic patients with type 2 diabetes. *Pak J Nutr* 2007;6(2):111 - 6.

83. Iqbal N, Vetter ML, Moore RH, *et al.* Effects of a low-intensity intervention that prescribed a low-carbohydrate vs. a low-fat diet in obese, diabetic participants. *Obesity (Silver Spring)* 2010;18(9):1733-8.

84. Itsiopoulos C, Brazionis L, Kaimakamis M, *et al.* Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study. *Nutr Metab Cardiovasc Dis* 2011;21(9):740-7.

85. Jenkins DJA, Kendall CWC, McKeown-Eyssen G, *et al.* Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: A randomized trial. *JAMA* 2008;300(23):2742-53.

86. Jimenez-Cruz A, Bacardi-Gascon M, Turnbull WH, *et al.* A flexible, low-glycemic index Mexican-style diet in overweight and obese subjects with type 2 diabetes improves metabolic parameters during a 6-week treatment period. *Diabetes Care* 2003;26(7):1967-70.

87. Jönsson T, Granfeldt Y, Ahrén B, *et al.* Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. *Cardiovasc Diabetol* 2009;8:35.

88. Kahleova H, Matoulek M, Malinska H, *et al.* Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with Type 2 diabetes. *Diabet Med* 2011;28(5):549-59.

89. Krebs JD, Elley CR, Parry-Strong A, *et al.* The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes. *Diabetologia* 2012;55(4):905-14.

90. Lasa A, Miranda J, Bulló M, *et al.* Comparative effect of two Mediterranean diets versus a low-fat diet on glycaemic control in individuals with type 2 diabetes. *Eur J Clin Nutr* 2014;68(7):767-72.

91. Lee YM, Kim SA, Lee IK, *et al.* Effect of a Brown Rice Based Vegan Diet and Conventional Diabetic Diet on Glycemic Control of Patients with Type 2 Diabetes: A 12-Week Randomized Clinical Trial. *PLoS One* 2016;11(6):e0155918.

92. Li R, Liu F, Cui S. Effectiveness of 30% low-carbohydrate diet in the treatment of type 2 diabetes mellitus and its effect on patients' body mass index. *J Med Theory Pract* 2021;34(8):1316-7. (Chinese).

93. Li S, Lin G, Chen J, *et al.* The effect of periodic ketogenic diet on newly diagnosed overweight or obese patients with type 2 diabetes. *BMC Endocrine Disorders* 2022;22:34.

94. Li Z-Y, Zhou Y-L. Effect of nutritional education of low glycemic index foods on type 2 diabetic patients. *Nurs Pract Res* 2011;8(1):7-8. (Chinese).

95. Liu K. Dietary intervention strategies for prevention and treatment of type 2 diabetes mellitus [Ph.D.]. Chongqing: The Third Military Medical University; 2016. (Chinese).

96. Liu X, Lu Y, Li M, *et al.* Effectiveness of low glycemic index diet for obese type 2 diabetes. *Shandong Med J* 2011;51(47):95-6. (Chinese).

97. Liu X, Qiao J, Qin Y, *et al.* Effect of ketogenic diet and energy-limiting balanced diet on body composition, blood glucose, and lipids in overweight T2DM patients. *Chin J Clin Healthc* 2020;23(6):823-6. (Chinese).

98. Lousley SE, Jones DB, Slaughter P, *et al.* High carbohydrate-high fibre diets in poorly controlled diabetes. *Diabet Med* 1984;1(1):21-5.

99. Luger M, Holstein B, Schindler K, *et al.* Feasibility and efficacy of an isocaloric high-protein vs. standard diet on insulin requirement, body weight and metabolic parameters in patients with type 2 diabetes on insulin therapy. *Exp Clin Endocrinol Diabetes* 2013;121(5):286-94.

100. Ma Y, Olendzki BC, Merriam PA, *et al.* A randomized clinical trial comparing low–glycemic index versus ADA dietary education among individuals with type 2 diabetes. *Nutrition* 2008;24(1):45-56.

101. Marco-Benedí V, Pérez-Calahorra S, Bea AM, *et al.* High-protein energy-restricted diets induce greater improvement in glucose homeostasis but not in adipokines comparing to standard-protein diets in early-onset diabetic adults with overweight or obesity. *Clin Nutr* 2020;39(5):1354-63.

102. McLaughlin T, Carter S, Lamendola C, *et al.* Clinical efficacy of two hypocaloric diets that vary in overweight patients with type 2 diabetes - Comparison of moderate fat versus carbohydrate reductions. *Diabetes Care* 2007;30(7):1877-9.

103. Mehling C. Comparison of low glycemic index high carbohydrate, high glycemic index high carbohydrate and monounsaturated fat-enriched diets on insulin sensitivity in the treatment of impaired glucose tolerance [M.Sc.]. Ann Arbor: University of Toronto (Canada); 2000.

104. Mohammadi S, Arefhosseini SR, Jafarabadi MA, *et al.* Regulation of serum lipid profile, glucose, insulin, and adiponectin in obese diabetic women under diet therapy: A randomized clinical controlled study. *Iran Red Crescent Med J* 2017;19(1).

105. Mollentze WF, Joubert G, Prins A, *et al.* The safety and efficacy of a low-energy diet to induce weight loss, improve metabolic health, and induce diabetes remission in insulin-treated obese men with type 2 diabetes: a pilot RCT. *Int J Diabetes Dev Ctries* 2019;39(4):618 - 25.

106. Nicholson AS, Sklar M, Barnard ND, *et al.* Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet. *Prev Med* 1999;29(2):87-91.

107. Ning G, Li W. Effectiveness of a 30% low-carbohydrate diet in the treatment of type 2 diabetes mellitus and the effect on patients' blood lipid levels. *J Chin Prescr Drug* 2020;18(6):191-2. (Chinese).

108. Parker B, Noakes M, Luscombe N, *et al.* Effect of a high-protein, high-monounsaturated fat weight loss diet on glycemic control and lipid levels in type 2 diabetes. *Diabetes Care* 2002;25(3):425-30.

109. Pavithran N, Kumar H, Menon AS, *et al.* The Effect of a Low GI Diet on Truncal Fat Mass and Glycated Hemoglobin in South Indians with Type 2 Diabetes-A Single Centre Randomized Prospective Study. *Nutrients* 2020;12(1).

110. Pavithran N, Kumar H, Menon AS, *et al.* South Indian cuisine with low glycemic index ingredients reduces cardiovascular risk factors in subjects with type 2 diabetes. *International journal of environmental research and public health* 2020;17(17):1 - 17.

111. Pedersen E, Jesudason DR, Clifton PM. High protein weight loss diets in obese subjects with type 2 diabetes mellitus. *Nutr Metab Cardiovasc Dis* 2014;24(5):554-62.

112. Perna S, Alalwan TA, Gozzer C, *et al.* Effectiveness of a hypocaloric and low-carbohydrate diet on visceral adipose tissue and glycemic control in overweight and obese patients with type 2 diabetes. *Bahrain Medical Bull* 2019;41(3):159 - 64.

113. Rizkalla SW, Taghrid L, Laromiguiere M, *et al.* Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men: a randomized controlled trial. *Diabetes Care* 2004;27(8):1866-72.

114. Rock CL, Flatt SW, Pakiz B, *et al.* Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: a randomized controlled trial. *Diabetes Care* 2014;37(6):1573-80.

115. Ruggenenti P, Abbate M, Ruggiero B, *et al.* Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. *Diabetes* 2017;66(1):75-86.

116. Ruggenenti P, Cortinovis M, Trillini M, *et al.* Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). *Diabetes Res Clin Pract* 2022;185.

117. Saslow LR, Daubenmier JJ, Moskowitz JT, *et al.* Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes. *Nutr Diabetes* 2017;7(12):304.

118. Saslow LR, Kim S, Daubenmier JJ, *et al.* A randomized pilot trial of a moderate carbohydrate diet compared to a very low carbohydrate diet in overweight or obese individuals with type 2 diabetes mellitus or prediabetes. *PLoS One* 2014;9(4):e91027.

119. Sato J, Kanazawa A, Makita S, *et al.* A randomized controlled trial of 130 g/day low-carbohydrate diet in type 2 diabetes with poor glycemic control. *Clin Nutr* 2017;36(4):992-1000.

120. Shen X, Bao L, Zhou H, *et al.* Application of dietary intervention with low glycemic index in the treatment of orthopedic patients with type 2 diabetes mellitus. *China Mod Doctor* 2021;59(15):19-22. (Chinese).

121. Shige H, Nestel P, Sviridov D, *et al.* Effect of weight reduction on the distribution of apolipoprotein A-I in high-density lipoprotein subfractions in obese non-insulin-dependent diabetic subjects. *Metabolism* 2000;49(11):1453-9.

122. Skytte MJ, Samkani A, Petersen AD, *et al.* A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. *Diabetologia* 2019;62(11):2066 - 78.

123. Stentz FB, Brewer A, Wan J, *et al.* Remission of pre-diabetes to normal glucose tolerance in obese adults with high protein versus high carbohydrate diet: randomized control trial. *BMJ Open Diabetes Res Care* 2016;4(1):e000258.

124. Sun J-Q, Zhang X-Y, Zong M, *et al.* Investigation of low glycemic index diet on blood glucose, lipid profile and body weight control in patients with type 2 diabetes. *Chin J Endocrinol Metab* 2007;23(6):541-3. (Chinese).

125. Sun Q, Wu G. Clinical efficacy of low-carbohydrate diet in the treatment of type 2 diabetes mellitus. *China Pharm* 2020;29(S2):102-3. (Chinese).

126. Tang W. Clinical efficacy of 30% low-carbohydrate diet in the treatment of type 2 diabetes. *Clin Res* 2021;29(3):98-9. (Chinese).

127. Tay J, Luscombe-Marsh ND, Thompson CH, *et al.* Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. *Am J Clin Nutr* 2015;102(4):780-90.

128. Thomsen MN, Skytte MJ, Samkani A, *et al.* Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. *Diabetologia* 2022;10.1007/s00125-021-05628-8.

129. Uusitupa M, Laitinen J, Siitonen O, *et al.* The maintenance of improved metabolic control after intensified diet therapy in recent type 2 diabetes. *Diabetes Res Clin Pract* 1993;19(3):227-38.

130. Visek J, Lacigova S, Cechurova D, *et al.* Comparison of a low-glycemic index vs standard diabetic diet. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2014;158(1):112-6.

131. Walker KZ, O'Dea K, Nicholson GC, *et al.* Dietary composition, body weight, and NIDDM. Comparison of high-fiber, high-carbohydrate, and modified-fat diets. *Diabetes Care* 1995;18(3):401-3.

132. Wang C-M. Effect of Nutrition Therapy of Low Glycemic Index Foods on Type 2 Diabetic Patients. *West China Med J* 2009;24(12):3137-9. (Chinese).

133. Wang L-L, Wang Q, Hong Y, *et al*. The Effect of Low-Carbohydrate Diet on Glycemic Control in Patients with Type 2 Diabetes Mellitus. *Nutrients* 2018;10(6):661.

134. Wang X, Chu J, Hao S, *et al*. Effect of dietary intervention on glucose and lipids in elderly diabetic patients. *Chin J Clin Res* 2015;28(10):1319-21;25. (Chinese).

135. Wang Y-L, Yao Y-N, Yang X-L. Clinical study of the changing of bodyweight (BW)and fasting blood glucose (FBG) in obese patients with type 2 diabetes on a low-carbohydrate diet (LCD). *J Xinjiang Med Univ* 2009;32(7):914-6. (Chinese).

136. Watson N, Dyer K, Buckley J, *et al*. Effects of Low-Fat Diets Differing in Protein and Carbohydrate Content on Cardiometabolic Risk Factors during Weight Loss and Weight Maintenance in Obese Adults with Type 2 Diabetes. *Nutrients* 2016;8(5):289.

137. Westman EC, Yancy WS, Jr., Mavropoulos JC, *et al*. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. *Nutr Metab (Lond)* 2008;5:36.

138. Wolever TM, Jenkins DJ, Vuksan V, *et al*. Beneficial effect of low-glycemic index diet in overweight NIDDM subjects. *Diabetes Care* 1992;15(4):562-4.

139. Wolever TMS, Gibbs AL, Mehling C, *et al*. The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: No effect on glycated hemoglobin but reduction in C-reactive protein. *Am J Clin Nutr* 2008;87(1):114-25.

140. Wu W, Liu C. Effect of low glycemic index diet on blood glucose, blood lipid and nutritional intake in patients with type 2 diabetes mellitus. *J Hubei Minzu Univ (Med Edn)* 2020;37(3):54-6. (Chinese).

141. Xue D. Effect of a Mediterranean diet on glucose and lipid metabolism in patients with type 2 diabetes. *Electron J Pract Clin Nurs Sci* 2020;6(5):106-7. (Chinese).

142. Yamada Y, Uchida J, Izumi H, *et al*. A non-calorie-restricted low-carbohydrate diet is effective as an alternative therapy for patients with type 2 diabetes. *Intern Med* 2014;53(1):13-9.

143. Ye B, Chen L. Effect of low glycemic index diet based on goal-setting theory on the intervention of patients with type 2 diabetes. *Diabetes World* 2021;18(2):133. (Chinese).

144. Yu Y. Effect of low glycemic index diet in patients with type 2 diabetes. *Med J Chin People's Health* 2020;32(9):127-9. (Chinese).

145. Zahedi M, Akhlagh SA, Aboomardani M, *et al*. Efficacy of mediterranean diet on blood biochemical factors in type II diabetic patients: A randomized controlled trial. *Gazi Med J* 2021;31(4A):714-8.

146. Zhao Y. Effect of low glycemic index diet on glucose and lipid metabolism in patients with type 2 diabetes. *China Health Care Nutr* 2018;4(28):41-2. (Chinese).

147. Zheng X, Zhou L, Wang J. Influence of low glycemic index (GI) diet on glucose and lipid metabolism of patients with type 2 diabetes. *China Mod Doctor* 2015;53(8):81-3;6. (Chinese).

148. Zhou W. Effects of diet interventions on glycemic control and cytokines changes in patients with type 2 diabetes mellitus [M.Nurs.]. Wuhan: Zhongnan University; 2011. (Chinese).

149. American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2022. *Diabetes Care* 2021;45(Supplement_1):S113-S24.

150. Kraus WE, Bhapkar M, Huffman KM, *et al.* 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. *Lancet Diabetes Endocrinol* 2019;7(9):673-83.

151. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. *Int J Obes Relat Metab Disord* 1997;21 Suppl 1:S5-9.

152. Zomer E, Gurusamy K, Leach R, *et al.* Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. *Obes Rev* 2016;17(10):1001-11.

153. Dong J-Y, Zhang Z-L, Wang P-Y, *et al.* Effects of high-protein diets on body weight, glycaemic control, blood lipids and blood pressure in type 2 diabetes: meta-analysis of randomised controlled trials. *Br J Nutr* 2013;110(5):781-9.

154. DiNicolantonio JJ, O'Keefe JH. Effects of dietary fats on blood lipids: a review of direct comparison trials. *Open Heart* 2018;5(2):e000871.

155. Zafar MI, Mills KE, Zheng J, *et al.* Low-glycemic index diets as an intervention for diabetes: a systematic review and meta-analysis. *Am J Clin Nutr* 2019;110(4):891-902.

156. Liese AD, Schulz M, Fang F, *et al.* Dietary Glycemic Index and Glycemic Load, Carbohydrate and Fiber Intake, and Measures of Insulin Sensitivity, Secretion, and Adiposity in the Insulin Resistance Atherosclerosis Study. *Diabetes Care* 2005;28(12):2832-8.

157. Wolever TM. Relationship between dietary fiber content and composition in foods and the glycemic index. *Am J Clin Nutr* 1990;51(1):72-5.

158. Reynolds A, Mann J, Cummings JH, *et al.* Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet* 2019;393(10170):434-45.

159. Seidelmann SB, Claggett B, Cheng S, *et al.* Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. *The Lancet Public Health* 2018;3(9):e419-e28.

160. Stephen AM, Champ MM, Cloran SJ, *et al.* Dietary fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and relationships to health. *Nutr Res Rev* 2017;30(2):149-90.

161. Martín-Peláez S, Fito M, Castaner O. Mediterranean Diet Effects on Type 2 Diabetes Prevention, Disease Progression, and Related Mechanisms. A Review. *Nutrients* 2020;12(8):2236.

162. Neuenschwander M, Hoffmann G, Schwingshackl L, *et al.* Impact of different dietary approaches on blood lipid control in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. *European Journal of Epidemiology* 2019;34(9):837-52.

163. Davis C, Bryan J, Hodgson J, *et al.* Definition of the Mediterranean Diet; A Literature Review. *Nutrients* 2015;7(11):9139-53.

164. Martínez-González MA, Fernández-Jarne E, Serrano-Martínez M, *et al.* Development of a short dietary intake questionnaire for the quantitative estimation of adherence to a cardioprotective Mediterranean diet. *Eur J Clin Nutr* 2004;58(11):1550-2.

165. US Department of Agriculture and US Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025 2020. Available from: DietaryGuidelines.gov.

166. Dyson PA, Twenefour D, Breen C, *et al.* Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. *Diabet Med* 2018;35(5):541-7.

167. Shirani F, Salehi-Abargouei A, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH) diet on some risk for developing type 2 diabetes: A systematic review and meta-analysis on controlled clinical trials. *Nutrition* 2013;29(7):939-47.

168. Rydhög B, Granfeldt Y, Sundquist K, *et al.* Paleolithic diet fraction in post hoc data analysis of a randomized cross-over study comparing Paleolithic diet with diabetes diet. *Clin Nutr Open Sci* 2021;38:73-80.

Figure Legends

Figure 1. PRISMA flowchart of data selection

Figure 2. Risk of bias of included studies. [a] The "period and carryover effects" domain was only for crossover RCTs (n = 16), and other domains were for all included studies (n = 107).

Figure 3. Efficacy of different eating patterns on glycemic control, anthropometrics, serum lipid profiles, and comparative attrition rate. I, intervention arm; C, control arm; No., Number of direct comparisons; Incons., P value of inconsistency test (node-splitting method); MD, mean difference; PMD, difference in percentage change from baseline; FPG, fasting plasma glucose; HbA_{1c}, glycated hemoglobin; FIns, fasting insulin; IR, insulin resistance; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triacylglycerol; TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol. Thick dashed referred to the null value, and thin dashed referred to the MCID threshold. Unless otherwise specified using "vs", the effect sizes were experimental patterns vs control. I^2 values were for network heterogeneity, including both direct and indirect comparisons.

Tables

Table 1. Eligibility criteria

Inclusion		Exclusion	
Type	Criteria	Type	Criteria
P	Adults with type 2 diabetes mellitus or prediabetes	I	Any prescribed between-group difference on exercise, antihyperglycemic medications, insulin injection, or other co-interventions; added a single supplement, or single specified food which did not provide macronutrients; or use meal replacement to provide an appreciable percentage of energy intake; or total energy intake (TEI) < 800 kcal/d (3.3 MJ/d); or the adjustment of intervention during the trial;
I	Contain at least one arm of the interventions as follows: caloric restriction (CR), high-fiber diet (fiber), Dietary Approaches to Stop Hypertension (DASH), high-protein diet (HPD), high-fat diet (HFD), low-carbohydrate diet (LCD), low-glycemic-index diet (LGID), Mediterranean diet (Med), Nordic diet (ND), Paleolithic diet (Paleo), Portfolio diet (PfD), and vegetarian/vegan/plant-based diet (VD). The macronutrients and food group intake can be as prescribed or as actual.		
C	Contained standard diabetes diet, e.g. ADA 2003 diet [7]; *ad libitum*; general nutrition counselling; or placebo (no intervention); or contain two or more intervention arms.		
O	Reported at least one outcome as follows, where fasting plasma glucose (FPG) was the primary outcome of this meta-analysis: glycemic control, including FPG, glycated hemoglobin (HbA_{1c}), fasting insulin (FIns) and insulin resistance (IR); anthropometrics, including weight, body mass index (BMI), waist circumference (WC), waist-to-hip	Duration	less than four weeks or one month for parallel RCTs or any phase of crossover RCTs; or intermittent intervention

Inclusion		Exclusion	
Type	Criteria	Type	Criteria
	ratio (WHR), and body fat rate (BFR), systolic blood pressure (SBP) and diastolic blood pressure (DBP); serum lipid profiles, including triacylglycerol (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL); renal function, including serum creatinine, serum urea, serum uric acid and (estimated) glomerular filtration rate; other dichotomous outcomes, including attrition rate, remission of T2DM, incidence of hypoglycemia, incidence of drug or insulin discontinuation, incidence of T2DM from PreD.	S	single-arm or self-controlled trials
		Other	Data availability: trials not completed, or without data analysis and published reports; or articles with inappropriate or insufficient data
S	Randomized controlled trials (RCT)		
Other	Language: English or Chinese		

P, participants; I, interventions; C, comparators; O, outcomes; S, study types.

Table 2. Characteristics of included studies

Study Information						Intervention		Arms and characteristics										
Basic Information										Participants ‡			Nutrition Intake §					
Study ID	Origin	Type	Objective	RoB	Duration (week)	Intensity †	Arm	Size	Sex ratio	Age (years)	BMI (kg/m^2)	TEI	Pr	Fat	CHO	GI	fiber
Al-Jazzaf	Kuwait	S	P	T2DM	SC	6	3	control	16	0.563	51.9 ± 12.8	34.6 ± 4.8	2270	17	33	49	73	25
2007[38]								LGID	16	0.438	55.3 ± 8.9	33 ± 3	2376	17	36	47	61	25
								LGID	18	0.611	48.2 ± 8	34.4 ± 5.4	1806	18	35	51	62	26
Azadbakht	Iran	S	X	T2DM	H	8	2	control	31	0.581			2165	15	28	57		
2011[39]								DASH	31	0.581			2189	16	29	55		
Bahado-Singh 2015[40]	Jamaica	S	P	T2DM	SC	24	3	control	24		43 ± 2.3	27.1 ± 0.8		30	32	45		25
								LGID	29		42.5 ± 2	26.11 ± 0.78		30	30	45		32
Barnard	USA	S	P	T2DM	SC	74	2	control	50	0.660	54.6 ± 10.2	35.9 ± 7	1422	21	34	47		18
2006/9[41, 42]								VD	49	0.551	56.7 ± 9.8	33.9 ± 7.8	1366	15	22	66		27
Brand	Australia	S	X	T2DM	SC	12	3	control	16	0.375	62 ± 9	25 ± 5	1623	19	31	46	90	26
1991[43]								LGID	16	0.375	62 ± 9	25 ± 5	1654	22	30	44	77	26
Brehm	USA	S	P	T2DM	SC	52	3	control	52	0.673	56.5 ± 8.91	35.9 ± 3.34	1550	18	28	54		
2009[44]								HFD	43	0.605	56.5 ± 8.91	35.9 ± 3.34	1550	16	38	46		
Breukelman	South	S	P	T2DM	H	16	2	control	13	0.692	58.3 ± 5.53	38.2 ± 10.66						
2019/21[45, 46]	Africa							LCD	10	0.600	54.2 ± 12.67	38.9 ± 6.06				10		
Brinkworth	Australia	S	P	T2DM	H	64	2	control	19	0.632	62.7 ± 7.85	33.3 ± 5.67		15	30	55		30
2004[47]								HPD	19	0.579	60.9 ± 7.85	33.6 ± 5.23		30	30	40		30
Brunerova	Czech	S	P	T2DM	H	12	3	control	13		51.2 ± 3.3	34.7 ± 3.6	1800	10	30	60		20
2007[48]								HFD	14		54.7 ± 3.8	33.4 ± 4.5	1800	10	45	45		20
Cao 2011[49]	China	S	P	T2DM	SC	52	2	control	45	0.378	53.2 ± 6.5	35.9 ± 6.5	1860	20	32	48		
								LCD	45	0.333	54.2 ± 6.2	35.4 ± 6.2	1980	22	45	33		
Ceriello	Spain	S	P	T2DM	SC	12	2	control	12	0.333		29.2 ± 3.81						
2014[50]								Med	12	0.250		29.8 ± 4.85						
Chandalia	USA	S	X	T2DM	H	6	4	control	13	0.077	61 ± 9	32.3 ± 3.9	2308	15	30	55		24
2000[51]								fiber	13	0.077	61 ± 9	32.3 ± 3.9	2308	15	30	55		50
Chen	China	S	P	T2DM	SC	76	3	control	42	0.619	64.1 ± 7.4	26.55 ± 3.69	1469	20	41	41		
2020a[52]	(Taiwan)							LCD	43	0.605	63.1 ± 10.5	27.31 ± 4.53	1430	23	46	25		
Chen	China	S	P	PreD	SC	12	2	control	43	0.628	51.9 ± 11.8	25.2 ± 4						
2020b[53]								LCD	57	0.596	54.9 ± 11.9	25.5 ± 2.9				25		
Choi 2013[54]	South	S	P	T2DM	SC	12	2	control	38		56 ± 8.6	26.74 ± 2.16	1785	20	20	60		
	Korea							CR	38		55.5 ± 7	27.36 ± 3	1396	20	20	60		

Study Information						Intervention		Arms and characteristics										
Basic Information										Participants ‡			Nutrition Intake §					
Study ID	Origin	Type	Objective	RoB		Duration (week)	Intensity †	Arm	Size	Sex ratio	Age (years)	BMI (kg/m^2)	TEI	Pr	Fat	CHO	GI	fiber
Coppell	New	S	P	T2DM	SC	24	2	control	48	0.563	58.4 ± 8.8	34.3 ± 5.8						
2010[55]	Zealand							fiber	45	0.622	56.6 ± 8.8	35.1 ± 6.1		15	30	55		40
Coulston	USA	S	X	T2DM	SC	6	4	control	8	0.375	66 ± 8.49	25.5 ± 2.26		20	20	60		
1989[56]								LCD	8	0.375	66 ± 8.49	25.5 ± 2.26		20	40	40		
Daly 2006[57]	UK	M	P	T2DM	SC	12	2	control	39	0.529	59.1 ± 10.57	36.7 ± 9	1434	21	33	45		14
								LCD	40	0.510	58.2 ± 11.07	35.4 ± 5	1290	26	40	34		10
Davis	USA	S	P	T2DM	SC	52	2	control	50	0.260	53 ± 7	37 ± 6	1810	19	31	50		17
2009[58]								LCD	55	0.182	54 ± 6	35 ± 6	1642	23	44	33		15
Ding	China	S	P	T2DM	H	24	2	control	37	0.725	58.7 ± 7.74	29.94 ± 3.85	2040	14	37	59		
2010[59, 60]								LGID	39	0.625	60.65 ± 6.92	30.24 ± 3.43	2012	14	30	59		
Durrer	Canada	S	P	T2DM	L	12	4	control	90	0.567	59 ± 8	35.1 ± 5.3	1667	22	40	40		
2021[61]								LCD	98	0.561	58 ± 11	36 ± 6	984	43	31	27		
Elhayany	Israel	M	P	T2DM	H	52	2	control	55	0.509	56 ± 6.1	31.8 ± 3.3	2221	20	30	50		15
2010[62]								Med	63	0.444	57.4 ± 6.1	31.1 ± 2.8	2221	20	30	50		30
								LCD	61	0.492	55.5 ± 6.5	31.4 ± 2.8	2221	20	45	35		30
Esposito	Italy	S	P	T2DM	L	208	2	control	107	0.514	51.9 ± 10.7	29.5 ± 3.6	1650					
2009[63]								Med	108	0.500	52.4 ± 11.2	29.7 ± 3.4	1650					
Fabricatore	USA	S	P	T2DM	SC	40	3	control	39	0.795	52.5 ± 8.12	35.8 ± 4.37	1676	19	33	50	65	16
2011[64]								LGID	40	0.800	52.8 ± 8.85	36.7 ± 5.06	1624	18	40	41	57	18
Fan 2010[66]	China	S	P	T2DM	SC	12	2	control	60									
								LGID	60									
Fan 2013[65]	China	S	P	T2DM	SC	12	2	control	25	0.462	69.1 ± 8.2	25.8 ± 2.5						
								LGID	26	0.462	69.3 ± 7.9	25.7 ± 2.7						
Fang 2016[68]	China	S	P	T2DM	SC	24	2	control	95	0.516	67.3 ± 9.8			15	25	60		
								LGID	105	0.495	68.2 ± 9.2			15	25	60	55	
Fang 2019[67]	China	S	P	T2DM	SC	24	2	control	283	0.481	56.78 ± 5.34		1835					
								CR	284	0.451	57.78 ± 5.14		1080					
Gannon	USA	S	X	T2DM	SC	5	4	control	12	0.167	61	31	2266	15	34	53		26
2003[70]								HPD	12	0.167	61	31	2235	30	30	40		29
Gannon	USA	S	X	T2DM	H	5	4	control	8	0.000	63.3	31	2825	15	30	55		24
2004[69]								LCD	8	0.000	63.3	31	2825	30	50	20		36
Goldstein	Israel	S	P	T2DM	SC	52	2	control	26	0.538	55 ± 8	33.3 ± 3	1937	19	40	43		
2011[71]								LCD	26	0.500	57 ± 9	33.1 ± 3.6	1725	24	58	20		

Study Information						Intervention		Arms and characteristics										
Basic Information										Participants ‡			Nutrition Intake §					
Study ID	Origin	Type	Objective	RoB	Duration (week)	Intensity †	Arm	Size	Sex ratio	Age (years)	BMI (kg/m^2)	TEI	Pr	Fat	CHO	GI	fiber
Gram-Kampmann 2022[72]	Denmark	S P	T2DM	SC	24	2	control	20	0.591	55.2 ± 12.66	35.2 ± 6.57	1600	23	28	48		30
							LCD	44	0.551	57.3 ± 6.3	32.5 ± 6.3	1642	23	63	13		16
Guldbrand 2012[73]	Sweden	M P	T2DM	SC	104	2	control	31	0.581	62.7 ± 11	33.8 ± 5.7	1700	24	31	44		
							LCD	30	0.533	61.2 ± 9.5	31.6 ± 5	1700	20	47	31		
Guo 2014[74]	China	S P	T2DM	SC	24	2	control	120		63.2 ± 13.1	26.98 ± 4.15						
							LGID	123		63.2 ± 13.1	26.42 ± 3.65						
Han 2021[75]	China	S P	T2DM	SC	24	2	control	61	0.535	53.74 ± 3.48	25.39 ± 3.95	1798	17	28	55		
							LCD	60	0.333	49.13±13.06		1796	29	58	14		
Hashemi 2019[76]	Iran	S P	T2DM	SC	12	2	control	40	0.600			1775	18	30	52		
							DASH	35	0.629			1771		27			
He 2017[77]	China	S P	T2DM	SC	12	3	control	75	0.413		24.47 ± 3.06						
							LGID	75	0.467		24.92 ± 3.01					55	
Heilbronn 2002[78]	Australia	S P	T2DM	SC	8	2	control	21	0.429	57.5 ± 9.6	33.4 ± 4.2	1436	22	17	61		30
							LGID	24	0.542	56 ± 9.4	34.2 ± 8.7	1442	22	18	59		29
Hockaday 1978[79]	UK	S P	T2DM	SC	52	2	control	39	0.487	50		1500	20	26	54		
							LCD	54	0.407	53		1500	20	40	40		
Hu 2018[80]	China	S P	PreD	SC	24	3	control	31	0.452	50.4 ± 3.2	25.9 ± 2.9		15	25	60		
							LCD	29	0.517	51.9 ± 4.2	25.9 ± 4		20	40	40		
Huang 2016[81]	China	S P	T2DM	SC	12	2	control	40	0.350	67.43 ± 8.43	25.79 ± 2.86						
							LGID	40	0.300	67.84 ± 8.71	25.92 ± 2.63						
Ikem 2007[82]	Nigeria	S P	T2DM	SC	8	2	control	17	0.412	58.2 ± 8.8	24.5 ± 3.4		20	20	60		
							fiber	35	0.543	57.6 ± 6.3	23.8 ± 3.3		20	20	60		40+
Iqbal 2010[83]	USA	S P	T2DM	SC	104	2	CR	74	0.054	60 ± 9.5	36.9 ± 5.3	1574	18	34	47		15
							LCD	70	0.157	60 ± 8.9	38.1 ± 5.5	1610	17	34	48		14
Itsiopoulos 2011[84]	Australia	S X	T2DM	SC	12	4	control	27	0.407	59	30.7 ± 4.9	1787	18	32	46		
							Med	27	0.407	59	30.7 ± 4.9	2229	14	39	44		
Jenkins 2008[85]	Canada	S P	T2DM	L	24	3	control	104	0.394	61 ± 9	31.2 ± 5.8	1690	21	31	48	84	
							LGID	106	0.387	60 ± 10	30.6 ± 6	1706	21	33	44	70	
Jimenez-Cruz 2003[86]	Mexico	S X	T2DM	H	6	2	control	14	0.571	59 ± 9	29.6 ± 5.8	1561	18	20	64	56	25
							LGID	14	0.571	59 ± 9	29.6 ± 5.8	1422	21	23	60	44	34
Jönsson 2009[87]	Sweden	S X	T2DM	SC	12	2	control	13	0.231	64 ± 6	30 ± 7	1878	20	34	42	55	26
							Paleo	13	0.231	64 ± 6	30 ± 7	1581	24	39	32	50	21

Study Information						Intervention		Arms and characteristics										
Basic Information										Participants ‡			Nutrition Intake §					
Study ID	Origin	Type	Objective	RoB	Duration (week)	Intensity †	Arm	Size	Sex ratio	Age (years)	BMI (kg/m^2)	TEI	Pr	Fat	CHO	GI	fiber
Kahleova 2011[88]	Czech	S P	T2DM	SC	24	4	control	37	0.514	57.7 ± 4.9	35 ± 4.6	1795	18	37	45		21
							VD	37	0.541	54.6 ± 7.8	35.1 ± 6.1	1736	16	37	50		25
Krebs 2012[89]	New Zealand	M P	T2DM	L	104	2	control	150	0.656	58 ± 9.2	36.7 ± 6.4	1695	20	30	48		24
							HPD	144	0.541	57.7 ± 9.9	36.6 ± 6.7	1714	21	33	46		23
Lasa 2014[90]	Spain	M P	T2DM	SC	52	2	control	67	0.522	67.2 ± 6.8	29.8 ± 2.8	2198	17	39	41		
							Med	74	0.608	67.4 ± 6.3	29.4 ± 2.9	2463	17	42	39		
							Med	50	0.680	67.1 ± 4.8	30.1 ± 3.1	2479	17	44	37		
Lee 2016[91]	South Korea	S P	T2DM	SC	12	2	control	47	0.745	58.3 ± 7	23.1 ± 2.4	1560	17	20	64		25
							VD	46	0.870	57.5 ± 7.7	23.9 ± 3.4	1496	15	19	72		34
Li 2011[94]	China	S P	T2DM	SC	12	2	control	78		51.8 ± 6.2			15	25	60		
							LGID	78		51.8 ± 6.2			15	25	60		
Li 2021[92]	China	S P	T2DM	SC	24	2	control	38	0.447	44.62 ± 1.3	35.38 ± 6.27				60		
							LCD	38	0.474	44.53 ± 1.28	35.41 ± 6.25				30		
Li 2022[93]	China	S P	T2DM	SC	12	3	control	29		37.1 ± 14.02	29.75 ± 6.07	1500	16	12	73		
							LCD	24		36.5 ± 13.67	29.04 ± 5.81	1500	16	78	11		
Liu 2011[96]	China	S P	T2DM	H	12	3	control	56					20	25	55		
							LGID	40								65	
Liu 2016[95]	China	S P	T2DM	L	12	3	control	30	0.500	49.7 ± 5.48	21.17 ± 1.37	1800	17	29	54		
							control	31	0.484	50.2 ± 6.12	21.42 ± 1.34	1800	17	29	54		
							LCD	30	0.500	49.8 ± 6.02	21.72 ± 1.37	1800	28	30	40		
							LCD	31	0.516	51.9 ± 5.01	21.21 ± 1.34	1800	28	30	40		
Liu 2020[97]	China	S P	T2DM	SC	4	3	CR	49	0.429	66.7 ± 8.7			15	25	55		
							LCD	49	0.469	66.9 ± 8.6			20	75	5		
Lousley 1984[98]	UK	S X	T2DM	SC	6	2	fiber	11		63.45 ± 7.17		1240	23	16	65		68
							LCD	11		63.45 ± 7.17		1240	22	44	37		13
Luger 2013[99]	Austria	S P	T2DM	SC	12	2	control	20	0.727	63.7 ± 5.2	33.6 ± 5.3	1235	17	29	50		22
							HPD	20	0.364	61 ± 5.7	33 ± 4.2	1273	26	35	38		22
Ma 2008[100]	USA	S P	T2DM	SC	52	2	control	21	0.476	51 ± 8.25	35.95 ± 6.75	1779	20	43	38	80	12
							LGID	19	0.579	56.31 ± 7.85	35.58 ± 7.46	1674	20	42	38	77	12
Marco-Benedí 2020[101]	Spain	S P	PreD	L	24	3	control	32	0.657	54.6 ± 8.11	32.3 ± 3.7	1600	18	30	52		
							HPD	35	0.474	56.5 ± 8.59	33.2 ± 3.63	1600	35	30	35		
McLaughlin 2007[102]	USA	S P	T2DM	SC	16	2	control	15	0.400	56 ± 7	31 ± 2.4		15	45	40		
							LCD	14	0.429	57 ± 7	31.4 ± 2.4		15	25	60		

Study Information						Intervention		Arms and characteristics										
Basic Information										Participants ‡			Nutrition Intake §					
Study ID	Origin	Type	Objective	RoB	Duration (week)	Intensity †	Arm	Size	Sex ratio	Age (years)	BMI (kg/m^2)	TEI	Pr	Fat	CHO	GI	fiber
Mehling	Canada	S	P	PreD	H	16	2	control	11	0.818	58.8 ± 13.27	29.4 ± 7.3	1714	17	28	53	83	23
2000[103]								LGID	13	0.769	55.2 ± 10.82	29.7 ± 4.33	1695	19	25	55	76	36
								LCD	11	0.818	6.88 ± 13.27	30.6 ± 5.64	1894	16	36	47	82	24
Mohammad	Iran	S	P	T2DM	SC	10	2	control	15	1.000	49.28 ± 7.75	32.45 ± 2.34	1787	12	40	48		
i 2017[104]								CR	15	1.000	49.63 ± 9.57	34.57 ± 5.62	1595	14	41	45		
Mollentze	South	S	P	T2DM	H	24	3	control	7	1.000	54.53 ± 6.48	40.1 ± 6.46	2477					
2019[105]	Africa							CR	9	1.000	55.64 ± 7.72	41.3 ± 4.41	2091					
Nicholson	USA	S	P	T2DM	SC	12	4	control	4	0.500	60		1526	18	31	51		20
1999[106]								VD	7	0.429	51		1409	14	11	75		26
Ning	China	S	P	T2DM	SC	52	2	control	31	0.452	57.63 ± 9.55	34.87 ± 3.25	1500			60		
2020[107]								LCD	31	0.419	57.52 ± 9.13	34.82 ± 3.16	1500	20	50	30		
Parker	Australia	S	P	T2DM	SC	8	4	control	28	0.643	62.08		1543	16	26	55		28
2002[108]								HPD	26	0.654	60.32		1587	28	28	42		24
Pavithran	India	S	P	T2DM	SC	24	3	control	18	0.333	52 ± 7.7	27.25 ± 2.72						
2020a[109]								LGID	18	0.500	52 ± 7.7	26.81 ± 5.04					45	
Pavithran	India	S	P	T2DM	H	24	3	control	40	0.325	51.93 ± 7.43	26.75 ± 3.29	1450	16	21	66		
2020b[110]								LGID	40	0.375	54.43 ± 7.57	26.4 ± 3.03	1511	16	24	62	45	
Pedersen	Australia	S	P	T2DM	SC	52	3	control	33	0.303	61	35 ± 4.6	1666	21	34	11		
2014[111]								HPD	31	0.323	58	36 ± 6.12	2005	26	35	39		
Perna	Italy	S	P	T2DM	SC	13	3	control	9	0.556	67.78 ± 5.87	32.41 ± 2.91	1600	18	23	59		
2019[112]								LCD	8	0.750	59.5 ± 9.48	30.3 ± 2.13	1600	22	46	32		
Rizkalla	France	S	X	T2DM	SC	4	2	control	12	0.000	54 ± 6.93	31 ± 3.46	2291	20	37	38	71	
2004[113]								LGID	12	0.000	54 ± 6.93	31 ± 3.46	2222	21	37	36	39	
Rock	USA	M	P	T2DM	SC	52	4	control	67	0.473	55.5 ± 9.2	36.2 ± 4.3		20	20	60		
2014[114]								HFD	66	0.481	57.3 ± 8.6	36.2 ± 4.7		25	30	45		
Ruggenenti	Italy	S	P	T2DM	L	24	3	control	36	0.289	59.5 ± 7.1	29.6 ± 3.8	1760	18	34	48		
2017[115]								CR	34	0.194	60.2 ± 7.2	30 ± 3.9	1571	20	36	44		
Ruggenenti	Italy	S	P	T2DM	L	104	2	control	50	0.180	62.8 ± 8.7	32.1 ± 3.1	1783	17	43	39		21
2022[116]								CR	53	0.245	64.9 ± 7.5	32.3 ± 3.7	1592	18	43	39		20
Saslow	USA	S	P	T2DM	L	52	2	control	16	0.889	55.1 ± 13.5	36.9 ± 6.93	1681	16	40	36		
2014/7[117, 118]								LCD	14	0.563	64.8 ± 7.7	35.9 ± 6.84	1535	25	62	19		
Sato 2017[119]	Japan	S	P	T2DM	SC	24	2	LCD	30	0.233	60.5 ± 10.5	27.27 ± 3.9	1371	19	34	43		
								CR	32	0.250	58.4 ± 10	27.11 ± 4.27	1605	16	29	49		

Study Information						Intervention		Arms and characteristics											
Basic Information										Participants ‡			Nutrition Intake §						
Study ID	Origin	Type	Objective	RoB		Duration (week)	Intensity †	Arm	Size	Sex ratio	Age (years)	BMI (kg/m^2)	TEI	Pr	Fat	CHO	GI	fiber
Shen	China	S	P	T2DM	SC	8	2	control	46	0.435	61.78 ± 7.05	23.91 ± 2.12						
2021[120]								LGID	46	0.391	62.11 ± 6.71	24.04 ± 2.19					55	
Shige	Australia	S	P	T2DM	SC	12	3	control	12		57.5 ± 11.8	32.6 ± 4.7	1541	17	9	73		
2000[121]								HFD	12		58.1 ± 9	33.1 ± 2.8	1596	18	32	50		
Skytte	Denmark	S	X	T2DM	H	6	3	control	28	0.286	64 ± 7.7	30.1 ± 5.2		17	33	50		
2019[122]								LCD	28	0.286	64 ± 7.7	30.1 ± 5.2		30	40	30		
Stentz	USA	S	P	PreD	H	24	4	control	12	0.019	41.1 ± 5.89	37.4 ± 5.89		15	30	55		
2016[123]								HPD	12	0.250	43.1 ± 4.5	40.5 ± 6.24		30	30	40		
Sun 2007[124]	China	S	X	T2DM	SC	4	4	control	42	0.500	68.6 ± 7.3	25.32 ± 2.7	1471				77	
								LGID	42	0.500	68.6 ± 7.3	25.32 ± 2.7	1493				55	
Sun 2020[125]	China	S	P	T2DM	SC	12	3	control	30	0.500	57.9 ± 10.4			30	45	25		
								LCD	30	0.467	57.6 ± 10.3			20	25	55		
Tang	China	S	P	T2DM	SC	12	3	control	45	0.444	40.18 ± 6.32					60		
2021[126]								LCD	45	0.467	40.25 ± 6.26		1600			30		
Tay 2015[127]	Australia	S	P	T2DM	L	52	4	control	57	0.491	58 ± 7	35.1 ± 4.1	1700	17	30	53		
								LCD	58	0.362	58 ± 7	34.2 ± 4.5	1700	28	58	14		
Thomsen	Denmark	S	P	T2DM	L	6	4	control	33	0.545	67 ± 8.8	33.2 ± 5.1	2044	17	33	50		48
2022[128]								LCD	34	0.412	66.4 ± 6.9	33.6 ± 4.6	2058	30	40	30		36
Uusitupa	Finland	S	P	T2DM	SC	52	2	control	46	0.391	54.16 ± 6.45	33.21 ± 4.78	1713					
1993[129]								CR	40	0.475	52.13 ± 6.61	33.88 ± 5.51	1628					
Visek	Czech	S	X	T2DM	H	12	2	control	20	0.400	62.7 ± 5.8	32 ± 4.2	1745	18	41	37	68	18
2014[130]								LGID	20	0.400	62.7 ± 5.8	32 ± 4.2	1676	18	38	38	49	18
Walker	Australia	S	X	T2DM	SC	12	2	control	24	0.625	58.3 ± 10.29	29.2 ± 3.43	1506	24	23	50		34
1995[131]								HFD	24	0.625	58.3 ± 10.29	29.2 ± 3.43	1554	22	36	40		25
Wang	China	S	P	T2DM	SC	12	2	control	53	0.528	50.1 ± 5.2			15	25	60		
2009a[132]								LGID	56	0.536	49.1 ± 5.6			15	25	60	55	
Wang	China	S	P	T2DM	SC	24	2	control	20		56.1 ± 1.3	30.23 ± 0.34	1800	15	25	60		
2009b[135]								LCD	20		57.3 ± 1.2	30.28 ± 0.39	1800	30	50	20		
Wang	China	S	P	T2DM	SC	24	2	control	50	0.360	71.8 ± 10.6	26.05 ± 2.82		20	25	55		
2015[134]								LGID	50	0.400	70.5 ± 10.4	25.32 ± 4.01						
Wang	China	S	P	T2DM	L	12	3	control	25	0.480	61.2 ± 11.71	24.62 ± 5.17	1732	18	26	56		
2018[133]								LCD	24	0.458	66.79 ± 9.12	24.29 ± 3.36	1808	19	42	39		
Watson	Australia	S	P	T2DM	L	12	4	control	29	0.448	55 ± 8	34.4 ± 4.7	1421	21	22	50		29

Study Information					Intervention		Arms and characteristics										
Basic Information									Participants ‡			Nutrition Intake §					
Study ID	Origin	Type	Objective	RoB	Duration (week)	Intensity †	Arm	Size	Sex ratio	Age (years)	BMI (kg/m^2)	TEI	Pr	Fat	CHO	GI	fiber
2016[136]							HPD	32	0.469	54 ± 8	34.3 ± 5.4	1490	29	30	35		25
Westman	USA	S	P	T2DM	H	24	2	LGID	29	0.793	50 ± 8.5	37.9 ± 6	1335	20	36	44		
2008[137]							LCD	21	0.667	51.2 ± 6.1	37.8 ± 6.7	1550	28	59	13		
Wolever	Canada	S	X	T2DM	SC	6	4	control	6	0.500	63 ± 9.8	32.1 ± 5.88	1388	20	23	57	86	33
1992[138]							LGID	6	0.500	63 ± 9.8	32.1 ± 5.88	1388	20	23	57	58	34
Wolever	Canada	S	P	T2DM	SC	52	4	control	48	0.500	60.4 ± 7.93	30.1 ± 4.33	1890	20	31	47	63	21
2008[139]							LGID	55	0.661	60.6 ± 7.48	31.6 ± 4.49	1800	21	27	52	55	36
							LCD	53	0.463	58.6 ± 8.82	31.1 ± 4.41	2020	19	40	39	59	23
Wu 2020[140]	China	S	P	T2DM	SC	12	2	control	52	0.442	53.03 ± 6.74	24.28 ± 3.25	1764	17	33	53		
							LGID	52	0.462	53.16 ± 6.9	24.53 ± 3.12	1679	19	33	51		
Xue 2020[141]	China	S	P	T2DM	SC	24	3	control	40	0.475	60.01 ± 2.54	25.91 ± 1.48					
							Med	40	0.425	55.23 ± 5.99	25.98 ± 1.72		15	25	60		
Yamada	Japan	S	P	T2DM	SC	24	2	CR	12	0.583	63.2 ± 10.2	27 ± 3	1610	17	32	51		
2014[142]							LCD	12	0.417	63.3 ± 13.5	24.5 ± 4.3	1634	25	45	30		
Ye 2021[143]	China	S	P	T2DM	SC	12	3	control	50		67 ± 1.3						
							LGID	50			68 ± 0.9						
Yu 2020[144]	China	S	P	T2DM	SC	12	3	control	150	0.387	59.98 ± 4.34	21.22 ± 3.34				83	
							LGID	150	0.407	60.01 ± 4.58	21.25 ± 3.44					69	
Zahedi	Iran	S	P	T2DM	SC	24	2	control	123	0.772	57.8 ± 8.9	31.21 ± 2.49					
2021[145]							Med	105	0.771	56.8 ± 9.5	30.14 ± 3.21						
Zhao	China	S	P	T2DM	SC	8	2	control	40	0.275	60 ± 3			15	25	60		
2018[146]							LGID	40	0.325	59.1 ± 3.5						55	
Zheng	China	S	P	T2DM	SC	8	2	control	37	0.459	59.8 ± 7.2	23.9 ± 2.7		15	25	60		
2015[147]							LGID	37	0.405	60.1 ± 6.7	24.1 ± 2.9					55	
Zhou	China	S	P	T2DM	SC	12	3	control	31	0.581		23.47 ± 3.2					
2011[148]							LGID	31	0.710		24.31 ± 3.22						

† Intensity was defined as: 1 = no intervention, 2 = only nutrition consultations or group discussion; 3 = provide detailed menus; 4 = provide prepared/prepackaged foods; 5 = metabolic wards.

‡ Age and BMI were presented as mean ± standard deviation. The sex ratio was female percentage.

§ Macronutrients (protein, fat and carbohydrate) were presented as the percentage of total energy intake (TEI%). The units of total energy intake and fiber were kcal/d and g/d, respectively.

S, single-center; M, multicenter; P, parallel; X, crossover; T2DM, type 2 diabetes mellitus; PreD, prediabetes; RoB, risk of bias; H, high; SC, some concerns; L, low; CR, caloric restriction; DASH, Dietary Approaches to Stop Hypertension; fiber, high-fiber diet; HFD, high-fat diet; HPD, high-protein diet; LCD, low-carbohydrate diet; LGID, low-glycemic-index diet; Med, Mediterranean diet; Paleo, Paleolithic diet; VD, vegetarian, vegan or plant-based diet; BMI, body mass index; TEI, total energy intake; Pr, protein; CHO, carbohydrate; GI, glycemic index. Data of nutrition intake were either prescribed or estimated from the mean of reported values from 24-hour self-reported dietary records. A 60-kg average individual or 2000-kcal average TEI was used for nutrition intake estimation if needed.

Table 3. Summary of findings

Efficacy[†]	Intervention	Direct Evidence		Indirect Evidence		Network Meta-analysis[‡]		
		Mean and 95% *CrI*	Quality	Mean and 95% *CrI*	Quality	Mean and 95% *CrI*	SUCRA	Quality
FPG (*MD*, mmol/L), MCID = 0.80								
Small (0.80 to 1.40)	fiber	-1.2 (-2.2, -0.057)	M[e]	-2.4 (-6.2, 1.4)	M[e]	-1.3 (-2.3, -0.22)	0.827	M
	LGID	-0.93 (-1.2, -0.64)	M[b]	-0.63 (-3.1, 1.8)	M[e]	-0.94 (-1.2, -0.65)	0.746	M
	DASH	-0.92 (-2.5, 0.70)	L[ae]			-0.92 (-2.5, 0.70)	0.639	L
	LCD	-0.72 (-1.0, -0.39)	M[bb]	-1.7 (-2.7, -0.63)		-0.82 (-1.1, -0.51)	0.651	M[g*]
	CR	-1.1 (-1.8, -0.51)	M[b]	0.15 (-0.93, 1.2)	VL[dee]	-0.81 (-1.4, -0.25)	0.645	L[g]
Trivial (0.00 to 0.80)	VD	-0.63 (-1.6, 0.29)	M[e]			-0.64 (-1.6, 0.29)	0.524	M
	Paleo	-0.50 (-2.2, 1.2)	L[ee]			-0.50 (-2.2, 1.2)	0.460	L
	Med	-0.45 (-1.1, 0.15)	L[be]			-0.45 (-1.1, 0.15)	0.405	L
	HPD	-0.29 (-0.88, 0.30)	L[ee]			-0.29 (-0.88, 0.30)	0.308	L
	HFD	-0.0078 (-0.79, 0.77)	VL[bee]			-0.0078 (-0.79, 0.77)	0.171	VL
HbA_{1c} (*MD*, %), MCID = 0.50								
Moderate (0.80 to 1.40)	DASH	-1.2 (-2.2, -0.23)	M[a]			-1.2 (-2.2, -0.23)	0.905	M
Small (0.50 to 0.90)	fiber	-0.42 (-1.3, 0.41)	L[ee]	-2.5 (-4.5, -0.53)	L[bf]	-0.74 (-1.5, 0.035)	0.712	L[g*]
	LGID	-0.73 (-0.95, -0.52)	L[bf]	0.35 (-1.1, 1.8)	VL[eef]	-0.71 (-0.93, -0.49)	0.762	L
	LCD	-0.63 (-0.85, -0.41)	L[bbf]	-0.95 (-1.6, -0.29)	M[f]	-0.67 (-0.88, -0.46)	0.721	L
Trivial (0.00 to 0.50)	Med	-0.46 (-0.90, -0.021)	L[ef]			-0.46 (-0.90, -0.021)	0.521	L
	Paleo	-0.40 (-1.5, 0.71)	L[ee]			-0.40 (-1.5, 0.71)	0.471	L
	CR	-0.51 (-1.1, 0.033)	M[e]	-0.11 (-0.74, 0.53)	VL[bee]	-0.34 (-0.76, 0.072)	0.412	M
	VD	-0.32 (-0.89, 0.25)	M[e]			-0.32 (-0.89, 0.25)	0.402	M
	HPD	-0.18 (-0.57, 0.21)	L[ee]			-0.18 (-0.57, 0.21)	0.272	L
	HFD	-0.11 (-0.63, 0.42)	L[ee]			-0.11 (-0.63, 0.42)	0.222	L
FIns (*PMD*), MCID = 0.08								
Large (> 0.16)	fiber	-0.22 (-0.52, 0.084)	L[ae]	-0.18 (-0.73, 0.37)	L[ee]	-0.21 (-0.46, 0.052)	0.794	L
Moderate (0.12 to 0.16)	LGID	-0.16 (-0.30, -0.025)	M[bb]	0.041 (-0.32, 0.40)	VL[dee]	-0.14 (-0.27, -0.0098)	0.683	M
Small (0.08 to 0.12)	LCD	-0.10 (-0.21, 0.0060)	L[bbe]	-0.27 (-0.60, 0.055)	L[de]	-0.12 (-0.22, -0.02)	0.628	M[†]
	HPD	-0.09 (-0.26, 0.082)	M[e]			-0.09 (-0.26, 0.082)	0.530	M
Trivial (0.00 to 0.08)	Med	-0.075 (-0.26, 0.10)	VL[bee]			-0.075 (-0.26, 0.10)	0.476	VL
	VD	-0.065 (-0.46, 0.33)	L[ee]			-0.065 (-0.46, 0.33)	0.467	L
	HFD	-0.050 (-0.26, 0.16)	VL[bee]			-0.050 (-0.26, 0.16)	0.408	VL

	Paleo	0.021 (-0.36, 0.41)	L[ee]			0.021 (-0.36, 0.41)	0.306	L
IR (*PMD*), MCID = 0.05								
Large (> 0.12)	HPD	-0.22 (-0.37, -0.07)	M[e]			-0.22 (-0.37, -0.07)	0.863	M
	LGID	-0.16 (-0.28, -0.04)	M[e]			-0.16 (-0.28, -0.04)	0.709	M
	HFD	-0.15 (-0.43, 0.13)	M[e]			-0.15 (-0.43, 0.13)	0.631	M
Moderate	Med	-0.098 (-0.19, 0.01)	M[e]			-0.098 (-0.19, 0.01)	0.482	M
(0.08 to 0.12)	LCD	-0.086 (-0.17, 0.0030)	M[e]			-0.086 (-0.17, 0.0030)	0.440	M
Trivial (0.00 to 0.05)	Paleo	-0.0010 (-0.29, 0.29)	L[ee]			-0.0010 (-0.29, 0.29)	0.257	L
weight (*MD*, kg), MCID = 3.00								
Small (3.00 to 5.00)	CR	-5.9 (-8.3, -3.4)	L[bbf]	-0.50 (-3.9, 2.9)	VL[eef]	-4.1 (-6.1, -2.0)	0.868	L[g*]
	LCD	-2.4 (-3.7, -1.0)	L[bbf]	-7.3 (-11, -3.8)	L[bf]	-3.0 (-4.3, -1.8)	0.743	L[g*]
	DASH	-3.0 (-9.0, 3.1)	L[ae]			-3.0 (-9.0, 3.1)	0.654	L
Trivial (0.00 to 3.00)	Paleo	-3.0 (-10, 4.0)	L[ee]			-3.0 (-10, 4.0)	0.637	L
	VD	-2.1 (-7.1, 3.0)	L[ee]			-2.1 (-7.1, 3.0)	0.560	L
	LGID	-1.1 (-2.8, 0.56)	VL[bbef]	1.1 (-5.6, 7.8)	VL[eef]	-1.1 (-2.7, 0.5)	0.435	VL
	fiber	-0.88 (-5.2, 3.5)	VL[aee]			-0.88 (-5.2, 3.5)	0.398	VL
	HFD	-0.61 (-3.3, 2.1)	VL[eef]			-0.61 (-3.3, 2.1)	0.343	VL
	Med	-0.58 (-3.8, 2.6)	L[ee]			-0.58 (-3.8, 2.6)	0.342	L
	HPD	-0.50 (-3.3, 2.1)	VL[eef]			-0.50 (-3.3, 2.1)	0.318	VL
BMI (*MD*, kg/m^2), MCID = 1.05								
Small (1.05 to 1.55)	LCD	-1.1 (-1.6, -0.59)	L[bbf]	-1.8 (-3.3, -0.34)	L[bf]	-1.2 (-1.7, -0.74)	0.816	L
	CR	-1.3 (-2.2, -0.35)	M[bb]	-0.71 (-2.4, 0.95)	L[be]	-1.1 (-1.9, -0.34)	0.756	M
Trivial (0.00 to 1.05)	Paleo	-1.0 (-3.8, 1.8)	M[e]			-1.0 (-3.8, 1.8)	0.598	M
	LGID	-0.74 (-1.3, -0.16)	L[bbf]	-0.022 (-2.5, 2.4)	VL[eef]	-0.73 (-1.28, -0.18)	0.543	L
	VD	-0.69 (-1.9, 0.57)	M[e]			-0.69 (-1.9, 0.57)	0.519	M
	Med	-0.66 (-1.4, 0.14)	VL[bbef]			-0.66 (-1.4, 0.14)	0.504	VL
	HPD	-0.43 (-1.5, 0.59)	L[ee]			-0.43 (-1.5, 0.59)	0.391	L
	HFD	-0.35 (-1.9, 1.1)	L[ee]			-0.35 (-1.9, 1.1)	0.375	L
	fiber	-0.29 (-1.8, 1.2)	L[ee]			-0.29 (-1.8, 1.2)	0.353	L
WC (*MD*, cm), MCID = 4.50								
Small (4.50 to 7.00)	DASH	-4.8 (-11, 1.1)	L[ae]			-4.8 (-11, 1.1)	0.776	L
Trivial (0.00 to 4.50)	CR	-4.5 (-7.4, -1.8)	M[bb]			-4.5 (-7.4, -1.8)	0.822	M
	Paleo	-4.0 (-12, 3.6)	M[e]			-4.0 (-12, 3.6)	0.669	M

	LCD	-2.8 (-4.7, -1.0)	M[bb]	-4.2 (-11, 2.8)	M[e]	-3.0 (-4.7, -1.3)	0.653	M
	HFD	-2.4 (-6.6, 1.8)	M[e]			-2.4 (-6.6, 1.8)	0.539	M
	VD	-2.3 (-6.4, 1.8)	M[e]			-2.3 (-6.4, 1.8)	0.534	M
	LGID	-2.1 (-4.0, -0.17)	M[e]	-1.2 (-8.0, 5.6)	VL[dee]	-2.1 (-3.9, -0.27)	0.499	M
	fiber	-1.1 (-5.3, 3.2)	L[ee]			-1.1 (-5.3, 3.2)	0.364	L
	Med	-0.77 (-4.4, 2.8)	L[ee]			-0.77 (-4.4, 2.8)	0.315	L
	HPD	0.53 (-2.8, 3.9)	VL[bee]			0.53 (-2.8, 3.9)	0.156	VL
SBP (*MD*, mmHg), MCID = 6.00								
Small (6.00 to	Paleo	-8.9 (-24, 6.4)	M[e]			-8.9 (-24, 6.4)	0.807	M
10.00)	DASH	-7.6 (-15, -0.29)	M[a]			-7.6 (-15, -0.29)	0.879	M
Trivial (0.00	HPD	-2.7 (-6.3, 0.71)	L[be]			-2.7 (-6.3, 0.71)	0.634	L
to 6.00)	LCD	-1.9 (-4.1, 0.38)	L[be]	-5.5 (-12, 1.3)	L[de]	-2.2 (-4.3, -0.10)	0.594	M[p*]
	CR	-2.3 (-6.8, 2.1)	L[be]	-0.12 (-8.1, 8.1)	L[ee]	-1.8 (-5.7, 2.0)	0.515	L
	fiber	-1.6 (-10, 7.3)	L[ee]			-1.6 (-10, 7.3)	0.477	L
	Med	-0.82 (-5.4, 3.8)	L[ee]			-0.82 (-5.4, 3.8)	0.401	L
	LGID	-0.92 (-4.0, 2.3)	VL[bee]	3.6 (-6.7, 14)	L[ee]	-0.76 (-3.7, 2.2)	0.385	VL
	VD	-0.11 (-6.2, 6.1)	L[ee]			-0.11 (-6.2, 6.1)	0.339	L
	HFD	1.2 (-4.1, 6.4)	L[ee]			1.2 (-4.1, 6.4)	0.211	L
DBP (*MD*, mmHg), MCID = 3.50								
Small (3.50 to	Paleo	-4.0 (-13, 5.3)	M[e]			-4.0 (-13, 5.3)	0.708	M
7.00)	DASH	-3.7 (-10, 2.8)	VL[abe]			-3.7 (-10, 2.8)	0.737	VL
Trivial (0.00	HPD	-3.0 (-5.9, -0.068)	M[b]			-3.0 (-5.9, -0.068)	0.746	M
to 3.50)	CR	-2.6 (-6.4, 1.1)	L[be]	0.15 (-6.7, 7.0)	L[ee]	-2.0 (-5.2, 1.2)	0.610	L
	LCD	-2.0 (-3.9, 0.033)	L[be]	-3.7 (-9.3, 1.9)	L[be]	-2.0 (-3.8, -0.069)	0.627	M[p*]
	LGID	-0.49 (-3.1, 2.1)	L[ee]	0.18 (-8.2, 8.7)	L[ee]	-0.83 (-3.3, 1.7)	0.440	L
	fiber	-0.73 (-8.2, 6.7)	L[ee]			-0.73 (-8.2, 6.7)	0.448	L
	Med	-0.48 (-4.6, 3.7)	VL[bbee]			-0.48 (-4.6, 3.7)	0.400	VL
	HFD	0.77 (-3.7, 5.2)	L[ee]			0.77 (-3.7, 5.2)	0.255	L
	VD	0.98 (-3.9, 5.9)	L[ee]			0.98 (-3.9, 5.9)	0.243	L
TG (*MD*, mmol/L), MCID = 0.09								
Large (> 0.25)	Paleo	-0.50 (-1.1, 0.13)	M[e]			-0.50 (-1.1, 0.13)	0.834	M
	LCD	-0.26 (-0.38, -0.14)	M[b]	-0.45(-0.81, -0.094)	H	-0.29 (-0.40, -0.18)	0.758	M
	LGID	-0.26 (-0.35, -0.15)	M[b]			-0.26 (-0.35, -0.15)	0.674	M
Moderate	HPD	-0.23 (-0.46, -0.0030)	M[e]			-0.23 (-0.46, -0.0030)	0.615	M
(0.15 to 0.25)	Med	-0.20 (-0.41, 0.0050)	L[be]			-0.20 (-0.41, 0.0050)	0.548	L
	fiber	-0.19 (-0.50, 0.13)	L[ae]			-0.19 (-0.50, 0.13)	0.517	L

	HFD	-0.18 (-0.52, 0.16)	M[e]			-0.18 (-0.52, 0.16)	0.499	M
Small (0.09 to 0.15)	CR	-0.18 (-0.41, 0.048)	M[e]	0.0026(-0.30, 0.31)	L[ee]	-0.11 (-0.29, 0.066)	0.361	M
Trivial (0.00 to 0.09)	DASH	-0.040 (-0.53, 0.45)	VL[aee]			-0.040 (-0.53, 0.45)	0.310	VL
	VD	-0.024 (-0.36, 0.31)	VL[bee]			-0.024 (-0.36, 0.31)	0.246	VL
TC (*MD*, mmol/L), MCID = 0.26								
Moderate (0.40 to 0.52)	LGID	-0.48 (-0.64, -0.31)	M[bb]	-0.18 (-1.0, 0.69)	L[ee]	-0.46 (-0.62, -0.30)	0.875	M
Small (0.26 to 0.40)	DASH	-0.36 (-1.1, 0.42)	VL[aee]			-0.36 (-1.1, 0.42)	0.647	VL
	fiber	-0.29 (-0.79, 0.21)	M[e]	-0.47 (-1.4, 0.51)	M[e]	-0.33 (-0.76, 0.11)	0.675	M
Trivial (0.00 to 0.26)	Paleo	-0.20 (-1.3, 0.87)	L[ee]			-0.20 (-1.3, 0.87)	0.500	L
	Med	-0.18 (-0.47, 0.12)	M[e]			-0.18 (-0.47, 0.12)	0.483	M
	CR	-0.23 (-0.53, 0.074)	L[be]	0.027 (-0.52, 0.58)	L[ee]	-0.17 (-0.43, 0.089)	0.472	L
	LCD	-0.12 (-0.29, 0.049)	L[be]	-0.35 (-0.80, 0.11)	L[de]	-0.17 (-0.32, -0.012)	0.470	M[p*]
	HPD	-0.15 (-0.44, 0.14)	M[e]			-0.15 (-0.44, 0.14)	0.439	M
	HFD	-0.12 (-0.52, 0.28)	L[ee]			-0.12 (-0.52, 0.28)	0.393	L
	VD	-0.11 (-0.58, 0.37)	L[ee]			-0.11 (-0.58, 0.37)	0.386	L
LDL (*MD*, mmol/L), MCID = 0.10								
Moderate (0.25 to 0.40)	DASH	-0.37 (-0.89, 0.15)	L[ae]			-0.37 (-0.89, 0.15)	0.773	L
	LGID	-0.37 (-0.48, -0.25)	M[b]	-0.19 (-0.83, 0.45)	L[ee]	-0.35 (-0.47, -0.24)	0.866	M
Small (0.10 to 0.25)	CR	-0.39 (-0.62, -0.15)	M[bb]	0.096 (-0.26, 0.46)	L[ee]	-0.24 (-0.44, -0.039)	0.694	L[g]
	fiber	-0.24 (-0.62, 0.14)	M[e]	-0.21 (-1.1, 0.65)	L[ee]	-0.24 (-0.35, 0.21)	0.648	M
	HPD	-0.11 (-0.31, 0.088)	M[e]			-0.11 (-0.31, 0.088)	0.443	M
	LCD	-0.058 (-0.18, 0.062)	M[e]	-0.43(-0.75, -0.099)	H	-0.11 (-0.22, 0.0040)	0.444	M[g*]
	Paleo	-0.10 (-0.92, 0.72)	L[ee]			-0.10 (-0.92, 0.72)	0.454	L
Trivial (0.00 to 0.10)	HFD	-0.067 (-0.35, 0.21)	L[ee]			-0.067 (-0.35, 0.21)	0.361	L
	VD	-0.060 (-0.36, 0.24)	L[ee]			-0.060 (-0.36, 0.24)	0.351	L
	Med	-0.029 (-0.27, 0.21)	VL[bbee]			-0.029 (-0.27, 0.21)	0.284	VL
HDL (*MD*, mmol/L), MCID = 0.10								
Small (0.10 to 0.15)	LCD	0.11 (0.056, 0.16)	M[bb]	0.15 (0.027, 0.27)	M[b]	0.12 (0.073, 0.17)	0.840	M
Trivial (0.00 to 0.10)	CR	0.10 (0.0092, 0.19)	M[bb]	0.044(-0.095, 0.18)	VL[bde]	0.084 (0.0080, 0.16)	0.657	M
	DASH	0.081 (-0.15, 0.31)	VL[aee]			0.081 (-0.15, 0.31)	0.593	VL
	LGID	0.083 (0.028, 0.14)	M[bb]	-0.025 (-0.28, 0.23)	L[ee]	0.080 (0.028, 0.13)	0.640	M
	Paleo	0.080 (-0.18, 0.34)	L[ee]			0.080 (-0.18, 0.34)	0.584	L
	fiber	0.026 (-0.13, 0.19)	VL[aee]	0.22 (-0.041, 0.49)	L[de]	0.077 (-0.059, 0.22)	0.609	VL

Med	0.062 (-0.039, 0.16)	L[bbe]	0.062 (-0.039, 0.16)	0.547	L
HFD	0.040 (-0.074, 0.15)	M[ee]	0.040 (-0.074, 0.15)	0.447	M
HPD	-0.017 (-0.11, 0.072)	L[ee]	-0.017 (-0.11, 0.072)	0.200	L
VD	-0.045 (-0.17, 0.079)	VL[bee]	-0.045 (-0.17, 0.079)	0.139	VL

a. limitation (risk of bias); b. inconsistency (unexplained substantial heterogeneity); bb. severe inconsistency (unexplained substantial heterogeneity, downgrade 1 level); c. indirectness (from population, intervention, or outcomes); d. indirectness (intransitivity); e. imprecision; ee. severe imprecision (downgrade 2 levels); f. publication bias; g. incoherence; g*. incoherence (same direction, no downgrading). p*. greater precision. SUCRA, surface under the cumulative ranking curve; H, high quality of evidence; M, moderate; L, low; VL, very low.

[†] "Small", "moderate" and "large" referred to beneficial effects.

[‡] We only identified limitations when more than half of the included studies providing the evidence were at high risk of bias. For inconsistency, an I^2 value of greater than 75% was considered severe inconsistent. Even if meta-regression was done, we were not confident to explain heterogeneity using covariates, so every comparison with I^2 greater than or near 50% was considered inconsistent. Indirectness from population, intervention or outcomes was not detected for T2DM because of the aims of this study; however, if applying evidence to PreD populations, indirectness should exist. Intransitivity was determined if the effect size and the SUCRA seemed very unstable in the sensitivity analysis. Unstable SUCRA may denote differences in characteristics among studies that could modify effects in indirect comparison. Imprecision was determined if 95% CrI contained a null value, or the effect size showed statistical instability (change of significance) in the meta-regression and sensitivity analysis. Severe imprecision referred to those whose CrI was divided by the null value into two parts with a comparable ratio, or the mean was very trivial, close to null. Incoherence was determined if the comparisons showed significant inconsistency (the term in network meta-analysis). The network quality of evidence was downgraded if incoherence of different directions (i.e., positive and negative) existed. All ratings of the factors were agreed by three authors (B.-T.Z., F.-D.L., and J.-W.D.).

Table 4. Dietary suggestions for patients with different profiles

Well-controlled glycemia	Poor-controlled glycemia	Poor insulin sensitivity	Hypertriglyceridemia	Hypercholesterolemia	Low HDL level	General obesity	Central obesity	Hypertension
Well-controlled glycemia	Only poor-controlled glycemia: LGID; fiber; DASH	HPD	LCD; Paleo[†]	LGID	LCD	CR; LCD	LCD	DASH; HPD
	Poor-controlled glycemia	LGID; fiber	LGID	LGID	LCD	DASH	DASH; LCD	DASH
		Poor insulin sensitivity	LGID	LGID	LCD	LCD	LCD[†]	HPD
			Hypertriglyceridemia	LGID	LGID	LCD	Paleo[†]	HPD
				Hypercholesterolemia	CR	CR	DASH	DASH
					Low HDL level	LCD	LCD	DASH[†]
						General obesity	CR	Paleo[†]
							Central obesity	DASH
								Hypertension

[†] The evidence is uncertain.

Supporting Information Legends:

File S1. Full search strategy

File S2. Data extraction template

File S3. Correlation coefficients for estimation

File S4. Reason for exclusion

File S5. Fundings and conflicts of interest of included studies

File S6. Risk of bias assessment

File S7. Network plots

File S8. League tables and cumulative ranking curves

File S9. Forest plots

File S10. Heterogeneity and inconsistency test

File S11. Meta-regression

File S12. Sensitivity analysis

File S13. Publication bias

File S14. Minimal clinically important difference and thresholds for effects.


Identification of studies via databases and registers
Identification of studies via other methods
Identification
Screening
Included
Records identified from: * (n = 9 534, 9 358 from initial searching and 176 updated)
Databases (n = 9 360);
Registers (n = 174)
Records removed before screening: (n = 5 211)
Duplicate records removed (n = 4 466);
Records marked as ineligible by automation tools (n = 745);
Records removed for other reasons (n = 0)
Records identified from:
References (n = 3);
Manual searching (n = 8)
Records removed before retrieval: (n = 2)
having been included (n = 1)
conference abstract (n = 1)
Records screened for title (n = 4 323)
Records excluded (n = 3 419)
Records without abstracts (n = 14)
Records screened for abstract (n = 890)
Records excluded (n = 600)
Records sought for retrieval (n = 9)
Records excluded (n = 0)
Records assessed for eligibility (n = 304)
Records excluded: (n=199)
conference abstract and full paper not found (n = 20);
insufficient data (n = 23);
intervention method (n = 25);
duration (n = 12);
data not available (n = 16);
not a trial (n = 5);
other language (n = 1);
having not completed (n = 10);
not peer-reviewed nor thesis (n = 1);
outcome (n = 13);
participants (n = 9);
same dataset (n = 50);
study design (n = 6);
full text not found (n = 3);
risk of data authenticity (n=5)
Records assessed for eligibility (n = 9)
Records excluded (n = 3):
intervention method (n = 3)
Records included in review and for meta-analysis (n = 111)
*: Records identified by initial searching (October 2021): CENTRAL (n = 929), CINAHL and Open Dissertation (n = 297), NCT (n = 174), CNKI (n = 463), Embase (n = 1676), Global Index Medicus (n = 65), ProQuest Dissertation (n = 93), PubMed (n = 1333), Scopus (n = 1762), SinoMed (n = 170), WanFang Med (n = 539), Web of Science (n = 1857)
Records identified by updated searching (March 2022): Web of Science (n = 60), Scopus (n = 69), Google Scholar (n = 47)


(n = 16)[a] Period and carryover effects
Overall Bias
Selection of the reported result
Measurement of the outcome
Missing outcome data
Deviations from intended interventions
Randomization process
0
10
20
30
40
50
60
70
80
90
100
Low risk
Some concerns
High risk


(A) FPG
92 Trials, 4309 I, 3806 C
No. I2 Incons.
CR 7 77.8% 0.043*
DASH 1
fiber 3 0.0% 0.531
HFD 5 57.0%
HPD 8 47.1%
LCD 24 87.9% 0.085
LGID 30 58.3% 0.81
Med 6 65.2%
Paleo 1
VD 4 0.0%
LCD vs CR 3 78.8% 0.045*
LCD vs fiber 1 0.0% 0.553
LGID vs LCD 2 0.0% 0.967
Med vs LCD 1 26.3% 0.515
-2 -1 0 1
MD, mmol/L
(B) HbA1c
90 Trials, 4010 I, 3462 C
No. I2 Incons.
5 35.2% 0.346
1
2 59.5% 0.058
5 0.0%
8 0.0%
26 93.0% 0.352
28 74.6% 0.132
6 47.5%
1
4 0.0%
4 48.1% 0.356
1 77.4% 0.059
2 51.4% 0.186
1 0.0% 0.955
-2 -1 0 1
MD, %
(C) FIns
35 Trials, 1336 I, 1173 C
No. I2 Incons.
1 0.0% 0.896
3 56.0%
5 10.7%
13 88.5% 0.324
7 76.2% 0.292
3 87.1%
1
1
1 0.0% 0.884
1 64.2% 0.289
1 25.5% 0.483
-0.4 -0.2 0.0 0.2 0.4
PMD
(D) IR
21 Trials, 1057 I, 890 C
No. I2 Incons.
1
4 38.2%
7 33.1%
5 8.3%
4 0.0%
1
1 0.0% 0.613
-0.4 -0.2 0.0 0.2
PMD
(E) Weight
67 Trials, 3106 I, 2474 C
No. I2 Incons.
CR 6 99.6% 0.012*
DASH 1
fiber 2 0.0%
HFD 5 56.8%
HPD 8 71.9%
LCD 22 99.7% 0.010*
LGID 15 82.2% 0.523
Med 3 0.0%
Paleo 1
VD 2 0.0%
LCD vs CR 4 88.1% 0.012*
LCD vs fiber
LGID vs LCD 3 28.3% 0.863
Med vs LCD 1 45.2% 0.778
-10 -5 0 5
MD, kg
(F) BMI
62 Trials, 2598 I, 2229 C
No. I2 Incons.
6 82.0% 0.565
2 35.1%
2 0.0%
5 7.3%
20 99.8% 0.370
15 80.2% 0.571
7 92.7%
1
3 59.2%
2 62.7% 0.563
2 1.2% 0.846
1 0.0% 0.832
-4 -2 0 2
MD, kg/m2
(G) WC
41 Trials, 1856 I, 1613 C
No. I2 Incons.
5 82.4%
1
2 0.0%
2 0.0%
3 70.6%
13 91.7% 0.715
11 41.2% 0.805
2 58.4%
1
2 0.0%
2 0.0% 0.638
1 36.0% 0.680
-10 -5 0 5
MD, cm
(H) Attrition Rate
51 Trials
No. I2 Incons.
5 0.0% 0.468
1
2 53.9%
8 0.0%
19 0.0% 0.040*
9 0.0% 0.114
3 70.2%
3 8.1%
2 0.0% 0.409
2 38.2% 0.332
1 0.0% 0.238
0.25 0.5 1 2 4 8
RR


(I) SBP
53 Trials, 2250 I, 1920 C
No. I 2 Incons.
CR 5 57.2% 0.645
DASH 2 0.0%
fiber 1
HFD 3 0.0%
HPD 7 53.6%
LCD 17 63.9% 0.312
LGID 10 58.4% 0.404
Med 3 68.6%
Paleo 1
VD 3 33.9%
LCD vs CR 2 0.0% 0.647
LCD vs fiber
LGID vs LCD 3 10.8% 0.631
Med vs LCD
-15 -10 -5 0 5
MD, mmHg


(J) DBP
51 Trials, 2102 I, 1833 C
No. I 2 Incons.
5 59.5% 0.484
2 64.6%
1
3 17.7%
7 66.2%
15 84.3% 0.567
9 36.4% 0.874
3 89.3%
1
3 19.3%
2 0.0% 0.488
2 71.7% 0.197
-10 -5 0 5
MD, mmHg


(K) TG
85 Trials, 3792 I, 3262 C
No. I 2 Incons.
5 0.0% 0.346
1
3 1.9%
5 0.0%
7 0.0%
25 53.5% 0.323
27 72.1%
6 65.5%
1
4 61.7%
4 0.0% 0.346
2 0.0% 0.722
1 0.0% 0.771
-0.5 0.0 0.5
MD, mmol/L


(L) TC
84 Trials, 3700 I, 3184 C
No. I 2 Incons.
CR 7 58.1% 0.413
DASH 1
fiber 3 0.0% 0.748
HFD 4 0.0%
HPD 7 17.1%
LCD 24 57.4% 0.356
LGID 27 83.1% 0.506
Med 6 19.9%
Paleo 1
VD 3 0.0%
LCD vs CR 2 89.8% 0.418
LCD vs fiber 1 0.0% 0.758
LGID vs LCD 3 18.7% 0.257
Med vs LCD 1 0.0% 0.861
-1.0 -0.5 0.0 0.5
MD, mmol/L


(M) LDL
80 Trials, 3480 I, 2979 C
No. I 2 Incons.
6 90.5% 0.026*
1
3 0.0% 0.947
4 0.0%
8 35.1%
23 41.0% 0.037*
24 79.8% 0.599
5 82.2%
1
3 0.0%
3 68.1% 0.027*
1 0.0% 0.941
3 24.7% 0.166
1 0.0% 0.902
-0.5 0.0 0.5
MD, mmol/L


(N) HDL
84 Trials, 3608 I, 3033 C
No. I 2 Incons.
7 96.2% 0.487
1
3 69.9% 0.207
5 0.0%
8 0.0%
23 83.9% 0.534
23 86.0% 0.407
6 84.9%
1 -
4 66.2%
4 36.3% 0.494
1 78.3% 0.203
3 52.6% 0.310
1 83.1% 0.497
-0.2 0.0 0.2 0.4
MD, mmol/L